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INTRODUCTION 
 
Thyroid cancer is the most common endocrine cancer and 
accounts for 1% of all the malignant cases. Thyroid malignancy is 
overwhelmingly the commonest type of endocrine malignancy and it 
accounts majority of the mortality of the cases due to the endocrine cancers. 
Patients with thyroid cancer have varied presentations and they usually 
present with a solitary thyroid nodule or multi-nodular goiter. Of all the 
thyroid nodules, the incidence of malignant lesions is 5%. The majority of 
the patients with carcinoma of the thyroid have differentiated cancer 
varying in history from a papillary carcinoma to a follicular carcinoma 
and also undifferentiated carcinoma such as anaplastic carcinoma.  
Differentiated carcinoma of the thyroid gland is most prevalent in young 
adults with female and male ratio of 3:1.  
Cancer of the thyroid gland represents a spectrum of different 
histological entities with diverse clinical behavior. Generally there is a very 
low progression from differentiated carcinoma to anaplastic carcinoma in 
some cases. However, this transition takes decades to takes place in most 
instances. The evaluation of thyroid nodule is a problem that confronts the 
clinicians. The majority of thyroid nodules are benign, but any thyroid 
swelling might harbor malignancy demanding proper investigation to 
establish the diagnosis. The natural history of the thyroid carcinomas 
allows the surgeon to do thoughtful preoperative workup for the 
diagnosis. 
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The fine needle aspiration cytology (FNAC) is now the corner stone of 
investigation for many of these patients and evaluation. The clinical 
management of the well-differentiated thyroid carcinomas rests on the 
retrospective studies and individual clinical experience. The clinical 
management depends upon the low risk and high risk categories of the 
malignancy. The surgical management is the primary modality of the 
treatment in thyroid carcinoma. The surgical management ranges from 
hemithyroidectomy to total thyroidectomy and the neck node dissection range 
from the prophylactic neck node dissection to the functional neck dissection 
depending on the clinical presentation. The post operative management of 
the patients includes radioactive iodine therapy after the evaluation of the 
need for the therapy. The role of radiotherapy and chemotherapy are very 
limited in the management of the thyroid carcinoma.  
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REVIEW OF LITERATURE 
  Andres Vasalieus (1514-1564 A.D.), who is credited as the “Father 
of Anatomy” gave the first description of thyroid gland. Pathological swellings 
in the anterior surface of the neck have been recognized since ancient times. 
The Greeks were  the  first  to  allude  to  thyroid  gland  enlargements,  
referring  to  them  as bronchoceles or hernias of the wind pipe. The close 
anatomical association of these glands with the larynx led to the name of thyroid 
(shaped like a shield) after the designation given by Galen to the thyroid 
cartilage.  
        Several successful extirpations were described after the year 1500. With 
the advent of general anesthesia in the mid 19th century, improvements in 
surgical techniques, judicious selection of cases; and the antiseptic era which 
was heralded in 1866, the intra and post operative complications of 
thyroidectomies were looked upon and controlled.  This led to the beginning of 
the golden years of thyroidectomy in 1896 in the hands of such great surgeons 
as Billroth and Kocher in Europe, and William Halstead, Charles Mayo in united 
states, among many others. The surgeons perform thousands of 
thyroidectomies with a mortality which progressively reduced to less than 
1% from the high mortality era.   
Theodore Kocher is considered the greatest contributor to the field of 
thyroid surgery.  His efforts were recognized and rewarded in 1909 by the 
Nobel Prize in medicine for his work. Butlin review in 1887 included 50 
patients, 60% of them died soon after surgery. By 1901 mortality decreased 
by 34%. Two types of lesions with better prognosis, papillary carcinoma 
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and encapsulated carcinoma; were recognized. In 1920 Mayo clinic 
published a report with better surgical results. Duffy 1950 reported the link 
between child irradiation to head and neck and occurrence of thyroid 
carcinoma as radiation was routinely used for therapy of acne, tonsils, 
enlarged thymus. By 1960, radiation therapy for benign condition was 
abandoned.2 FNAC of thyroid was first described in the 1930‟s by Martin and 
Ellis. In 1950, the technique of FNAC was popularized in Scandinavia. It is 
Zajieek, the first pathologist to embrace FNAC in collaboration with Franzen 
at the Karoliska hospital defined the precise diagnostic criteria and 
determined the diagnostic accuracy.10  
 
Surgical Anatomy of the Thyroid Gland 
  Thyroid is a highly vascular gland, weighing about 15 to 25 grams, and 
consists of two lobes, united in mid line by the isthmus, which overlies the 
second and third tracheal rings enclosed between the layers of the deep 
cervical fascia. There may also be a pyramidal lobe present in 50% of cases 
and is remnant of the thyroglossal tract.11 Its surgical capsule is external to 
the true capsule and is only prominent posteriorly where it condenses to form 
the suspensory ligament of Berry to connect the lobes of the gland to the 
cricoid cartilage and the first two tracheal rings and this attachment causes the 
thyroid to move on swallowing. The lateral lobes lie between the great 
vessels of the neck and the tracheoesophageal structures and confined by 
their capsule.  
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Blood Supply  
The supply and drainage of blood to and from the thyroid involves two 
pairs of arteries, three pairs of veins, and a dense network of connecting 
vessels that mesh throughout the capsule of the gland.3 The superior 
thyroid artery begins as the first branch of the external carotid artery in 
80% of individuals and from the common carotid artery in the remainders 
and it divides at the superior pole of the gland to lie in the anterior and 
posterior surface of the lobe and it lies postero laterally and parallel to the 
external branch of the superior laryngeal nerve. The inferior thyroid arteries 
branch directly from the thyrocervical trunk and it usually gives off one or 
two branches, one directed cephalically to the superior parathyroid gland 
and another inferiorly to the inferior parathyroid gland and hence the 
inferior thyroid artery should be ligated beyond these take off sites. 
 
Lymphatic Drainage  
The so-called central compartment nodes are the primary site of 
drainage whereas the lymph nodes of the internal jugular, posterior triangle 
nodes that constitute the lateral neck nodes are the site of secondary 
drainage.13 It is postulated that the metastases to the upper and the 
submandibular nodes occur in the later stages once the pretracheal and 
paratracheal have become obstructed by metastases.14  
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Nerves Associated with the thyroid gland   
The thyroid gland is closely associated with two nerves namely 
the recurrent laryngeal and the external laryngeal nerves. Of the two nerves, 
the right recurrent laryngeal nerve branches from the vagus at the base of the 
neck, loops around the subclavian artery, and then extends into the thyroid 
bed 2 cm lateral to the trachea. The left recurrent laryngeal nerve branches 
from the vagus nerve at the level of the aortic arch and passes inferior 
and posterior to the arch, lateral to the ductus arteriosus. It then 
passes posterior to the carotid sheath and into the thyroid bed, where it is 
closer to and parallel to the tracheoesophageal groove than its counterpart on 
the other side of the neck. Recurrent nerve run behind the artery in 53% on 
right and 69% on left and run anterior to artery in 37% on right and 24% on 
left. Unusually the non-recurrent laryngeal nerve can branch directly from 
the vagus and pass directly to the thyroid and this non-recurrent nerve is found 
in 1-1.5% of patients.15  
The superior laryngeal nerves branch from the vagus nerve at the 
level of base of the skull and descend towards the superior pole along with 
the internal carotid artery. The smaller external branches are related with the 
inferior pharyngeal constrictor muscle on its lateral surface and usually 
descend anteriorly and also medially with the superior thyroid artery. The 
nerve takes a medial course in the neck and enters into the cricothyroid 
muscle within 1 cm of the superior thyroid artery‟s entry into the thyroid. If 
severed or entrapped during surgery, the nerve is at the risk of injury if the 
superior pole vessels are ligated too above the superior pole of the thyroid.9 
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Epidemiology of Thyroid Malignancies  
 The incidence of thyroid cancer is increasing from 3.59 per 1, 
00,000 persons in 1973 to 8.71 per 1, 00,000 persons in 2002 at 2.41 fold 
increase as per the U.S. Statistics.  There is increase in incidence of papillary 
carcinoma during this period from 2.71 to 7.71 per 1, 00,000 persons, a 2.91 
fold increase in the incidence.  
  Thyroid cancer is less common in children than in adults but still 
accounts for 1.4% of childhood malignancies.20 The incidence of thyroid 
cancer in children less than 15 years is approximately 0.5 per million per 
year, with a rapid rise occurring after the age of 5. In reality because of the 
fact that many thyroid cancers never become clinically apparent and as such 
are never diagnosed, the true incidence is not known. In an autopsy study 
Fukunaga and Yatani reported data from multiple countries that there was 
an 11 % overall incidence of occult papillary thyroid cancer.21 Female are 
affected more than males and the ratio is somewhere around 1:1.6 to 1:3.15 
Even though the overall incidence of differentiated thyroid cancer is more 
common among the females than in males, a nodule in a male is more likely to 
be malignant variety than in a females.23  
Overall papillary cancer is more common than follicular, which is more 
common than medullary, is more common than anaplastic. B.B. Yeole, 
reported that incidence of thyroid carcinoma in Bombay and other parts of 
India is quiet low in the both the sexes in comparison with international 
experience and preponderance to Muslims has been reported.24  
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Etiology of Thyroid Malignancies  
 1.  Radiation  exposure :  Exposure  to  radiation  is  the  
only  proved  thyroid carcinogen.25 A 10 to 20 year post radiation latency 
period was reported earlier but this has not been noted in the pediatric 
thyroid cancer cases that have resulted from the Chernobyl nuclear disaster in 
the Ukraine in 1986, where there has been a dramatic increase in such 
cancers as early as 1989.26 In contrast to external radiation, there is little 
evidence to suggest that internal radiation from I131 used for 
therapeutic or diagnostic medical purposes causes thyroid cancer in humans.27  
 
2. Hereditary factors: Among the thyroid malignancies, the 
medullary carcinoma is familial in 10% to 30% of cases. Patients with 
familial variety have the medullary carcinoma as an autosomal dominant in 
one of the three  clinical syndromic scenarios.  
i. Isolated Familial medullary thyroid carcinoma (FMTC)  
ii. Multiple Endocrine Neoplasia syndrome Type 2A (MEN 2A)  
iii. Multiple Endocrine Neoplasia syndrome Type 2B (MEN 2B)  
 
Patients with Cowden‟s syndrome and Gardner‟s syndrome, Werner‟s 
syndrome and FAP have an increased risk of benign and malignant neoplasms 
of the thyroid.21 About 6% of the patients with differentiated thyroid cancers 
have familial thyroid cancer.29 Papillary thyroid cancer accounts for 90% of 
familial non-medullary thyroid cancer.30  
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3. Family History: Thyroid cancer is one of the risk factors for 
the development of both medullary and well differentiated thyroid cancers. 
Familial medullary thyroid cancer occurs in association with other tumours as 
part of MEN2 syndromes.  
 
 4. Thyroid stimulating hormone elevation: An increased risk of 
thyroid cancer is seen in patients with chronic elevation of TSH. Animal 
experiments indicate that prolonged TSH stimulation can cause thyroid cancer.31 
Even though it is not clear in humans, increased TSH though not being 
sufficient to cause thyroid cancers may stimulate its growth once present.  
 
 5. Chronic Lymphocytic Thyroiditis: Thyroid lymphoma most often 
occurs against a background of autoimmune lymphocytic thyroiditis 
(Hashimoto‟s disease).  
 
 6. Solitary thyroid nodule: Presence of solitary thyroid nodule is 
also a risk factor for malignancy. The incidence of malignancy with in a clinically 
apparent SNT is approximately 5-10%. If imaging investigations show the 
nodule to be truly solitary, then the likelihood of it being malignant increases to 
about 20%.  
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Classification of Thyroid Malignancies 
PRIMARY  
1. Follicular epithelial cells 
Differentiated 
Papillary carcinoma  
Follicular carcinoma 
Undifferentiated  
Anaplastic carcinoma 
 
 
2. Para follicular cells                               Medullary carcinoma  
     3. Lymphoid cells                                    Lymphoma 
 
SECONDARY 
1. Metastatic  
2. Local infiltration 
Pathology and natural history of carcinomas  
    Papillary thyroid carcinoma 
The typical PTC on physical examination is firm with an irregular 
border, has a white color, and may contain micro calcifications. It can be 
classified as occult or intra thyroidal and extra thyroidal. At the time of 
presentation, upto 80%-90% of the primary lesions are confined to the gland.32 
Encapsulation of the tumour is seen in 10% of the cases.33 Tumour multi 
centricity is seen in 20% to 30% of cases in most of the studies. In 1971 
Woolner described papillary cancer seen by light microscopy: “The typical 
histological picture is a mixture of papillary excrescences and neoplastic 
follicles containing varying degrees of colloid.34  
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The percentage of papillary and follicular elements is varied. The 
nucleus is hypodense with large areas that appear empty and are apparently 
devoid of chromatin.35 Consequently, the nucleus appear opaque and are 
given many names including “clear”, “watery”, “pale”, or the most imaginative 
“Orphan Annie Eyes”. Consequently the diagnosis of PTC is based on a 
constellation of findings. In particular, papillae projecting into open spaces, as 
well as clear nuclei with prominent nuclear grooves are all important features 
of the diagnosis.  
Another important feature is the presence of psammoma bodies 
(Greek: psammoma - sand) which are laminated calcific areas.36 They are 
seen in 50% of cases in most series.37 Although the etiology is unclear it is 
believed to represent the remains of the dead papillae and are quiet specific 
for PTC and are rarely seen in other thyroid lesions.38  
Several variants of papillary cancer exist, some behave like typical 
PTC whereas others have a more aggressive behavior.  
 
Morphological variants of papillary thyroid carcinoma39  
Variants with similar clinical 
behavior 
 
Variants with more aggressive 
behavior 
Follicular Tall cell 
Micro papillary Diffuse sclerosing 
Encapsulated Solid Columnar 
Solid/Trabecular Oxyphil 
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The papillary cancer has a broad behavioral spectrum in general. 
There are evidence that small foci of PTC remain dormant for the duration of 
a person‟s life, and not infrequently regress or even disappear while 
metastatic sites of the same tumour continue to grow.40 The propensity for 
papillary cancer to spread in the lymphatics within and outside the gland is 
striking. 5-10% of patients present with distant metastases at some time in 
course of the disease.41 The natural prognosis of the metastatic cancer seems 
to be volume related. It is worse in patients with bone, lung and CNS 
metastases.42 The tall cell variant has a worse prognosis in all age groups.  
 
Follicular carcinoma of thyroid 
  Follicular cancers are encapsulated lesions  and  are  very  difficult  
to differentiate from its benign counterpart follicular adenomas. They are 
characterized microscopically by large nuclei, frequent and/or atypical mitotic 
figures, vascular invasion, and distant metastases.43 In contrast to papillary 
carcinoma intra thyroidal multifocal disease rarely occurs in follicular cancers. 
Instead these lesions are usually solitary, encapsulated and have a micro 
follicular histological pattern. The findings that constitute malignancy are not 
cytological but instead are histological features like transcapsular invasion 
and micro vascular invasion of the vessels along the thyroid capsule.Lymph 
node involvement is unusual and it occurs late in the course of the disease.  
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Follicular cancers are divided into “minimally invasive” and “widely 
invasive”.44 The minimally invasive forms are grossly encapsulated and the 
diagnosis depends upon the presence of vascular or capsular invasion. The 
widely invasive form is characterized by widespread infiltration of the blood 
vessels or the adjacent thyroid tissue. Tumours that represent a mixed form 
of papillary and follicular features, showing signs of follicular differentiation 
and also signs of papillary cancer should clinically regarded as papillary rather 
than follicular cancers.45  
 
Morphological variants of follicular thyroid carcinoma  
Hurthle cell variant (Oxyphil or Oncocytic carcinoma)  
Insular cell variant  
  30% to 50% of Hurthle cell carcinomas are associated with lymph 
node metastases, compared with 5% to 10% of follicular cancers.46 The 
Hurthle cell variant, unlike other follicular cells does not take up radioactive 
iodine. This variant occurs particularly in adult women and is usually solid, 
well vascularised and well encapsulated. The insular tumours were so named 
because the clusters of cells within it contain small follicles that resemble 
the pancreatic islet cells.47 Insular thyroid cancer is a more aggressive 
malignancy and is perceived to behave less favorably than the papillary and 
follicular cancers.48  
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Anaplastic carcinoma of the thyroid 
Anaplastic carcinoma is a devastating disease that usually overcomes 
the host in a matter of months, sometimes even weeks. They represent 5% 
to 14% of thyroid malignancies.49 The median age of onset of ATC is 
consistently in the seventh decade of life and the disease is characterized by 
female preponderance ranging from 55% to 77%.50 The anaplastic 
component is composed of varying proportions of spindle, polygonal and 
giant cells.51 In general, the lethality of anaplastic cancer should not be 
underestimated, even when minimal in size amid a background of 
predominately differentiated cancer. The natural history of this cancer is 
characterized by rapid and massive loco regional growth, dysphagia, SVC 
syndrome and finally asphyxiation or exsanguinations.  
Medullary carcinoma of the thyroid 
These malignancies are derived from the non epithelial para follicular 
or the C cells which have the ability to synthesize and secrete calcitonin. MTC 
typically arises from the upper portion of the thyroid where the C-cells are 
concentrated. These cells are derived from the neural crest and are therefore 
of neuro ectodermal origin. Hence the medullary carcinomas have histological 
and cytological features typical of other neuro endocrine tumours such as 
carcinoid tumours, pancreatic islet cell tumours and pheochromocytomas.52 
They occur in two basic forms, sporadic and familial. The sporadic type 
make up 70% to 90% of the total and the familial 10% to 20%.53 FNAC yields 
presumptive clues to the diagnosis of MTC. Spindle shaped or triangular cells 
with dendritic extensions are highly suggestive of MTC. Although amyloid 
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may be presumptively identified in Papanicolau stains, it is confirmed by 
restaining with Congo red. On gross examination it is firm, solid, grayish, 
or pale brown well demarcated from the surrounding tissues.  
Microscopically the typical appearance is that of polyhedral cells 
arranged in sheets or irregular trabeculae. In familial cases there are often 
microscopic foci of C-cell hyperplasia, or microscopic medullary carcinoma in 
areas of normal parenchyma, thus demonstrating multicentric tumour origin.54  
The natural history of this type of thyroid cancer depends upon 
whether the MTC is familial or sporadic and the syndromes associated 
with the cancer. The knowledge about the genetic makeup of the neoplasm 
impacts upon management as it allows for screening, early detection and 
prophylactic treatment. 
 
Characteristics of the sporadic and familial forms of MTC55  
 
 Sporadic 
Familial 
Non MEN MEN 2A MEN 2B 
Age at diagnosis  42 – 45 43 – 45 24 – 27 15 – 20 
Gender (F:M) 1 : 1 1 : 1 1 : 1 1 : 1 
Associated diseases None None 
Pheochromocytoma 
Hyperparathyroidism 
Pheochromocytoma 
Marfanoid habitus 
Mucosal neuromas 
GIT Ganglioneuromas 
Disease extent Unilateral Bilateral Bilateral Bilateral 
Lymphnode 
metastasis  
40 – 0% 10 –20% 14% 38% 
Distant metastasis  12% 0% 0 – 3% 20% 
Cured of MTC 14 – 30% 70 – 80% 56 – 100% 0% 
Dead of MTC 30% 0% 0 – 17% 50% 
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Clinical Presentation of Thyroid Carcinomas  
1. Thyroid swelling  
Thyroid  cancer  most  commonly  presents  as  a  single  neck  mass  
noted incidentally by the patient or the physician. A thyroid mass in a child 
no matter its size or consistency is highly suspicious of malignancy. 
Regardless of the sex, the mass in advanced years is likely to be 
malignant. Though many women develop thyroid cancer than in men, any 
given nodule in a man is more likely to be malignant. Although such words 
as hard with fixation can apply to a mass associated with thyroiditis, 
these features must be viewed with suspicion for malignancy.  
The opposite must not be assumed, however; soft masses with 
no fixation to the surrounding tissues are not necessarily benign. Rapid 
enlargement can be deceptive because of the tendency for intra lesion 
hemorrhage. On the other hand, the relentless and rapid growth that can 
be seen in anaplastic carcinoma is so impressive that its ominous nature is 
quiet obvious. Cystic lesions are more likely benign, but cystic carcinomas 
do occur. Solid lesions have a 21% risk of malignancy, cystic 7% and mixed 
lesions had a risk of 12%.56 5% to 10% of multiple nodules and 10% to 
20% of solitary nodules are malignant.  
 
2. Cervical lymphadenopathy  
In case of papillary carcinoma which is known for its lymphatic 
spread the patient present with cervical lymphadenopathy alone in 20% of 
cases and a mass in the thyroid with cervical lymphadenopathy in 13% of 
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cases. Children and young adults more often have palpable nodal 
metastases. Most studies report a 30% to 40% incidence of cervical nodal 
metastasis when therapeutic nodal dissections were performed.57 In 
medullary carcinoma metastases are mostly found in the neck and 
mediastinal lymph nodes, and may calcify. Sporadic cases of MTC are more 
prone for lymph nodal spread than the familial cases.  
In the presence of a seemingly normal thyroid gland, a lateral neck 
mass with biopsy proven thyroid tissue was previously misconceived to 
represent an embryonic nest of thyroid tissue and erroneously termed “lateral 
aberrant thyroid”. This presentation is now considered to be caused by 
metastatic well differentiated thyroid carcinoma from an occult primary within 
the gland until proved otherwise.58  
 
3. Symptoms related to the tumour growth  
These symptoms may infrequently precede or occur simultaneously 
with the development of a nodule, include hoarseness, dyspnoea and 
dysphagia, reflecting local infiltration of the recurrent laryngeal nerve, the 
trachea and the esophagus respectively. Horner‟s syndrome associated with a 
thyroid mass usually represents an ominous circumstance.  Large multinodular  
goiters  with  or  without  substernal extension can cause tracheal shift or 
impingement and alteration of the airway.59 Local compressive symptoms 
are a rule in case of anaplastic carcinoma. 
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4. Symptoms related to distant metastases  
Among the thyroid malignancies anaplastic carcinomas are quiet likely to 
have a distant metastasis which are usually pulmonary but can also involve 
bone, brain and soft tissues. Distant foci of the tumour are seen in 20% to 
50% of patients. Most distant metastases are found in the lung, liver and 
bone.60 They are found in more than 75% who die from thyroid carcinoma and 
lung metastasis account for almost 50% tumour related deaths.  
5. Symptoms related to hormonal derangement  
Thyroid cancer can present with hyperthyroid features with the 
incidence currently at about 5% to 10% in patients with Grave‟s disease. 
Papillary carcinoma accounts for 75% of thyroid cancers associated with 
Grave‟s disease.61 Patients who present with clinical evidence of thyroid cancer 
and have Grave‟s disease have more aggressive tumours, whereas patients 
with occult thyroid cancers who are treated for Grave‟s disease have an 
excellent prognosis. Diarrhea has been reported in 20% to 30% of cases of 
sporadic MTC at presentation often in patients with extensive disease.62  
The underlying  mechanism  is  still  to  be  clarified.  Prostaglandins, 
Vasoactive intestinal polypeptide, Calcitonin gene related peptide and Seratonin 
have all been suggested as mediators of this symptom. Although rare, 
concomitant Cushing‟s syndrome is the most striking presentation of 
sporadic MTC in some cases.63 This unusual phenomenon is explained by the 
common precursor of ACTH and calcitonin. When cortisol production is 
excessive and the tumour burden is too large for resection, bilateral 
adrenalectomy is the last resort.  
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Laboratory Evaluation  
 
Blood tests are not revealing in persons with most types of thyroid 
cancer. However the following blood tests may be helpful in some cases.  
1.  Thyroid function tests: The vast majority of thyroid cancers are 
clinically euthyroid. A malignant toxic thyroid nodule rarely causes 
hyperthyroidism.  
2.  Thyroglobulin: Thyroglobulin is present in normal serum in 
concentrations of 20 to 40 ng/ml, but elevation above this offers no specific 
information. Thyroiditis and   even   hyperthyroidism   may   be   responsible   
for   an   abnormal   high thyroglobulin.64 It should be noted that, eventhough 
diagnostic sensitivity has not been described, a thyroglobulin level of more 
than 10 times the upper limit of normal is highly suggestive of cancer.65 
Serum thyroglobulin levels > 2 ng/ml after thyroidectomy indicates 
presence of metastatic  disease  and  a  rise  in serum thyroglobulin in a 
patient with known metastases indicates progression of disease. 
Thyroglobulin levels of > 60 ng/ml suggest thyroid cancers.   
3. Plasma calcitonin: Of all the blood products, the plasma calcitonin has the 
most direct diagnostic value in determining the nature of the thyroid 
mass.66 Calcitonin levels are elevated in almost all patients with MTC. However 
in those patients who do have a normal baseline values, detections of micro 
lesions or C-cell hyperplasia associated with MEN2A or MEN2B can be 
accomplished with a pentagastrin or a calcium stimulation of calcitonin.67 
Normal calcitonin levels < 10 pg/ml. A stimulated value of < 30 pg/ml is 
considered normal and a value greater than 100pg/ml is abnormal.  
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4. Genetic testing: Genetic testing is available for family members at 
risk for developing medullary cancer. The ret proto-oncogene encodes a 
protein receptor, tyrosine kinase. Mutations of ret are associated in 95% of 
hereditary medullary thyroid cancers, MEN 2A, MEN 2B and FMTC.68  
 
5. Other   blood   tests:   Patients   with   MEN 2A   and 2B   have   
associated pheochromocytoma and hyperparathyroidism and hence those 
with  family history or those with features of either of these must be 
investigated for these disorders also.  
 
Fine Needle Aspiration Cytology  
 
Core needle biopsy has been used extensively in a few institutions 
in the United State and abroad but has failed to gain widespread 
acceptance. It is particularly helpful in diffuse diseases such as 
Hashimoto‟s thyroiditis and in forming the diagnosis of advanced malignant 
neoplasms. Most authors have been reluctant to use this technique in the 
evaluation of the single thyroid nodule because of the small but definitive risk 
of complication. FNAC has been instead, in matter of few years became an 
extremely popular technique for the evaluation of solitary thyroid nodules. 
Its approach is obvious, its quick and inexpensive, can be carried out in the 
office and risk of complications are minimal.69 Furthermore the material is 
suitable for immunohistochemical evaluation. Most papillary carcinomas and 
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other types of malignancy other than follicular carcinoma can be identified 
with ease. In most instances, the cytology report will be one of the following 
three:  
 
1.  Probably benign nodule, when the material is composed largely of 
colloid, histiocytes and few normal looking follicular cells. This will be 
indication for a conservative approach unless the clinical data suggests 
otherwise.70  
2.  Follicular neoplasm; when cellularity higher than that found in the 
usual hyper plastic nodule, but the nuclear features of papillary 
cancer are absent. The diagnosis of Hurthle cell neoplasm usually falls 
in the category.71 The presence of highly hyper chromatic nuclei, micro 
follicular or solid pattern, scanty colloid and necrotic debris suggest 
the prevalence of poorly differentiated cancer. The diagnosis of 
follicular neoplasm is an indication for removal of the nodule, unless this 
is contraindicated for medical reasons. 
3.  Papillary cancer, when the characteristic cytoarchitectural features of 
this tumor type are present, such as papillary fronds, psammomma 
bodies, nuclear pseudo inclusions, and nuclear grooves. It should be 
remembered that the ground glass nuclear feature is usually not 
apparent in cytological preparations; even when prominent in tissue 
sections. Concerning the follicular variant of papillary carcinoma, 
the nuclear change should be particularly well developed.72 In both the 
classic and the follicular variants of the tumor the colloid often exhibits a 
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peculiar streaking and smearing that can be compared with that of a 
bubble gum. The cytological diagnosis of papillary cancer is obviously 
an indication for therapeutic intervention, even if occasional surgical 
specimen may show only a papillary micro carcinoma. 
 
 
The performance of FNA may result in a partial or complete infraction 
of the tumor with only a thin rim of tissue preserved at the periphery. This 
complication is particularly common with hurtle cell tumors and it may result in 
transient elevation of Tg. Another complication of the procedure when carried 
out in cystic lesions has been the development of transient thyrotoxicosis.72 
 
Imaging in Carcinoma of Thyroid  
 
1. Radiograph: Standard radiographs provide limited information in 
the evaluation of a thyroid mass, and with the exception of identification 
of metastatic lung disease, provide no specific information. The chest 
radiograph should include the lower neck that the position of the trachea is 
visualized. When calcifications are seen in the gland and especially if they 
are bilateral bulky and near the junction of the upper two third and the 
lower one third, medullary cancer is suggested. Such calcification can also be 
seen in metastatic MTC in the cervical nodes.73  
 
2. Ultrasound: High frequency (7-13 MHz), small parts instruments 
have become widely available since mid 1980s and provide good spatial 
resolution and image quality. Intrathyroid nodules as small as 3 mm in 
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diameter and cystic nodules as small as 2 mm can be readily detected. Neck 
USG may confirm the presence of thyroid nodule when the findings on 
physical examination are equivocal. The diagrammatic representation of the 
neck showing the location or locations of any abnormal finding is a useful 
supplement to routine film images which serves as a reference for 
sonographer on follow up examinations.74 In patients with known thyroid 
cancer sonography can be useful in evaluating the extent of disease, both 
preoperatively and postoperatively.  In most instances, sonography is not 
performed routinely before thyroidectomy but can be useful in patients with 
large cervical masses for evaluation of nearby structures to exclude the 
possibility of direct invasion or encasement by tumor.  
 
3. CT and MRI: CT scan and MRI of the neck and the thorax is helpful 
in assessing the extent and relationship of larger thyroid tumours, particularly 
the involvement of the larynx, trachea, esophagus and the major 
vessels. The presence of metastatic cervical and mediastinal adenopathy is 
usually obvious in the CT and MRI.  
 
Abdominal CT is indicated when a pheochromocytoma is 
suspected. Advantage of MRI include multiplanar image acquisition, 
good soft tissue contrast and the fact that iodine containing contrast is 
not required, which can significantly hamper the postoperative radio 
nucleotide imaging. 
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4. Scintigraphy: The most important use of scintigraphic imaging 
of the thyroid tissue is to define areas of decreased or increased function 
(Cold or hot areas, respectively) relative to function of the remainder of the 
gland, provided that they are 1 cm in diameter. Almost all malignant 
nodules are hypo functioning; but more than 80% of benign nodules are 
nonfunctioning. Conversely, functioning nodules, particularly if they are 
more active than secondary tissue or the sole functioning tissue; are rarely 
malignant.  
Thyroid body scanning is performed with I131 in the follow up of 
patients with papillary and follicular thyroid cancer. Uptake by the neoplastic 
tissue is always lower than in normal and may be found only after TSH 
stimulation. For this reason sufficiently high dose of I131 should be given; and 
scanning should be performed 2 to 3 days after the dose, when 
background blood activity is low and when contrast is optimal.  
 
In a series of proved thyroid carcinomas that had been radioactively 
scanned 61% of the scans revealed cold nodules, 29% were normal scans 
and 10% showed hot spots at or near the malignant lesion. Malignancy has 
been shown to occur in 15% to 20% of cold nodules and in 5% to 9% of 
warm or hot nodules, mandating continued aggressive approach to 
clinically nodules even if they are not cold. In practice, if a thyroid nodule 
warrants removal on the basis of history or physical or cytological 
findings, a radioisotope study need not be done.  
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STAGING OF THYROID CANCER117  
TNM Staging Primary tumour (T)  
Tx Primary tumor cannot be assessed. 
T0 No evidence of primary tumor 
T1 Tumor 2 cm or less in greatest dimension and limited to the 
thyroid 
T1a Tumor 1 cm or less and limited to the thyroid 
T1b Tumor more than 1 cm but not more than 2 cm in greatest 
dimension and limited to the thyroid 
T2 Tumor more than 2 cm but not more than 4 cm in greatest 
dimension and limited to the thyroid 
T3 Tumor more than 4 cm in greatest dimension limited to the 
thyroid or any tumor with minimal extrathyroid extension (eg, 
extension to sternothyroid muscle or perithyroid soft tissues)  
T4a Moderately advanced disease 
Tumor of any size extending beyond the thyroid capsule to invade 
subcutaneous soft tissues, larynx, trachea, esophagus, or 
recurrent laryngeal nerve 
T4b Very advanced disease 
Tumor invades into the prevertebral fascia or encases carotid 
artery or mediastinal vessel. 
All anaplastic carcinomas are considered T4 tumors. 
T4a Intrathyroidal anaplastic carcinoma 
T4b Anaplastic carcinoma with gross extrathyroid extension 
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Regional Lymph Nodes (N) 
Regional lymph nodes are the central compartment, lateral cervical, and 
upper mediastinal lymph nodes.  
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
N1a Metastasis to Level VI (Pretracheal, paratracheal, and 
prelaryngeal/ Delphian Lymph nodes) 
N1b Metastasis to unilateral, bilateral, or contralateral cervical (Levels 
I, II, III, IV or V) or retropharyngeal or superior mediastinal lymph 
nodes (Level VII) 
 Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
 
Stage Grouping  
Separate stage grouping are recommended for papillary or 
follicular, medullary and anaplastic carcinoma.  
 
Papillary or Follicular carcinoma  
Stage Grouping of Papillary / Follicular carcinomas (<45 years) 
 
Under 45 years 
 
Stage I Any T Any N M0 
Stage II Any T Any N M1 
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45 years and older 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1 N1a M0 
 T2 N1a M0 
 T3 N1a M0 
Stage IV A T4a N0 M0 
 T4a N1a M0 
 T1 N1b M0 
 T2 N1b M0 
 T3 N1b M0 
 T4a N1b M0 
Stage IV B T4b Any N M0 
Stage IV C Any Any N M1 
 
Survival and Prognostic Features  
Overall survival in well differentiated carcinoma from various 
institutional series shows a better 10 year survival for papillary cancer, 
ranging between 74% and 93% as compared to follicular cancer, with a 
10 year survival of 43% to 94%. Although many institutions have 
reported their data based on these histologic subcategories, a more 
meaningful system is to categorize patients according to definite risk 
factors more pertinent to generating prognostic information. The risk 
categorization scheme developed at the Lahey clinic, by Cady and group 
carries the acronym AMES112 (Age, Metastatic disease, Extrathyroidal 
extension, Size). A group from Canada added an assessment of the DNA 
content by flow cytometry to this which carries the acronym DAMES with the 
DNA content, and showed that the high-risk patients with aneuploid 
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tumours have a poor long term survival. The initial system developed at 
the Mayo clinic group in 1987 by Hay and associates carried the acronym 
AGES (Age, Grade of the tumour, Extent of tumour, Size). A mathematical 
formula to develop a PS with different weights on these factors was 
developed. A more recent modification of this system is seen in MACIS 
(Metastasis, Age, tumor extent divided into Completeness of the surgery, 
Invasion and tumor Size). The MACIS scale is a more sophisticated post 
operative system modified from AGES scale. In addition some studies have 
reported that incomplete resection of the gland, vascular invasion, male sex, 
lymph node metastases, certain morphologic variants of PTC and tumour 
multicentricity are significant prognostic factors.  
 
Prognostic Risk Categorization Schemes  
AMES categorization scheme76  
 Low Risk High Risk 
Age Male <41, female <51 Male >40, female >50 
Metastases Extent 
 
 
Intrathyroidal papillary or 
follicular with minor 
capsular invasion 
Extrathyroidal papillary or 
Follicular with major 
capsular invasion 
Size <5 cm > 5 cm 
Definition 
 
 
 
A: Any low risk age group 
without metastases. 
B: High risk age without 
metastases and with 
low risk extent and size 
A: Any patient with 
metastases. 
B: High risk age with  
either high risk extent 
or size. 
Overall survival (OS)  98% 54% 
Disease survival 
(DFS) 
95% 55% 
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Management of Thyroid Carcinoma 
A. Management of differentiated carcinoma of the thyroid  
1. Surgery: The key decision in the surgical management of thyroid 
nodules or cancers is whom to operate on and how extensive a resection to 
perform.  
Extent of thyroidectomy  
A long standing controversy among endocrine surgeons has existed 
regarding the extent of surgical resection for well differentiated thyroid 
cancer. Technical contributions of surgeons such as Kocher, Lahey, Crile, 
Perzik, Attie, Thompson and others has established thyroidectomy safe and 
effective and it is the primary treatment for patients with well differentiated 
carcinomas of the thyroid. However, for low risk patients, conflicting views by 
experts persist. For patients in the high-risk category, there is much less 
disagreement regarding the extent of the surgery, although there are still some 
proponents of less than total or near total thyroidectomy. 
Acceptable surgical procedures to remove thyroid neoplasm include:  
i. Hemithyroidectomy (total removal of one lobe and the isthmus). 
ii. Sub-total thyroidectomy (total lobectomy leaving a rim of 2 to 4 gm of 
tissue in the upper lateral portion of the contralateral lobe) 
iii. Near-total thyroidectomy (total lobectomy and subtotal resection on 
the contralateral side to leave less than 1gm of thyroid tissue). 
(Hartley-Dunhill procedure) 
iv. Total thyroidectomy. 
  30 
 
The difference between a total thyroidectomy and a near total 
thyroidectomy usually depends on the particular anatomy of the thyroid in 
any given patient. There may be a small ledge of thyroid tissue, called the 
tubercle of Zuckerkandl, at the ligament of Berry that may limit safe resection 
of the thyroid gland.  
 
Arguments for and against conservative and radical surgeries in well-
differentiated cancers of thyroid81,82 
 
Issue Conservative surgery Radical surgery 
Prognostic risk factors An occasional low risk 
patients develop 
recurrence.  Who have 
20 year survival of 99% 
and 20 year DFS of 
>95% 
An occasional low risk 
patient develops 
recurrence.   
Safety of Surgery No risks of permanent 
complications. 
Minimal complications 
such as hypocalcemia or 
recurrent laryngeal 
nerve injury with 
experienced surgeons.  
Minimal complications 
with experience 
surgeons. 
Postperative iodine If necessary I131 ablation 
can be accomplished 
with no morbidity.  
Thyroid ablation with 
I131 is complicated with 
pain and decreased 
efficacy with thyroid 
remnant.  
Thyroglobulin Follow-up Not possible Possible and an accurate 
marker.  
Multicentricity and 
Recurrence 
Tumor multicentricity 
seems to have little 
prognostic significance.  
Eliminates the 
contralateral cancers at 
the sites of recurrence.  
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Setting apart all the controversies, total thyroidectomy is the 
treatment of choice for virtually all patients with PTC when postoperative 
radioiodine therapy is being considered. This basically includes all 
patients except those with occult PTC < 1 cm. Even in patients with low 
risk PTC, total or near-total thyroidectomy is associated with lower rates of 
recurrence and mortality. When a total thyroidectomy cannot be performed 
without injury to the recurrent laryngeal nerve or parathyroid glands, a near 
total thyroidectomy is performed and the small amount of thyroid tissue left 
behind can subsequently be ablated with radioactive iodine.  
This controversy also exists with follicular carcinomas, with 
conservative surgeons advocating less aggressive procedures for small 
tumours < l cm. However in most centers a total thyroidectomy with 
postoperative radioiodine ablation is performed for all tumours beyond stage 
I. A combination of total or near-total thyroidectomy and I131 ablation 
increases the sensitivity of diagnostic I131 total body imaging in the 
search of metastases and allows the destruction of residual microscopic 
disease. The removal of normal thyroid tissue is also a prerequisite for 
postoperative measurements of serum thyroglobulin, a tumour marker used to 
detect recurrent disease.  
 
Role of frozen section  
There  have  been  few  careful  reviews  of  the  value  of  frozen  
section examination in the management of thyroid cancer. Frozen section 
is unnecessary when a FNAC diagnosis is either benign or malignant. In case 
of suspect findings it would be of value and hence it is recommended that 
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frozen section be reserved for lesions with persistently non-diagnostic 
results on FNA, for confirmation of lymph node metastases and for thyroid 
nodules diagnosed during surgery and not previously sampled.76 Although the 
sensitivity of frozen section was only 62.5%, 58.3%, and 75% in benign, 
suspect and inadequate FNA cases respectively, the technique did permit 
the identification of some malignant lesions. The patients are undoubtedly 
spared of the second surgery to complete a total thyroidectomy when a 
malignant diagnosis is confirmed. Hence intraoperative frozen section for the 
thyroid nodular disease can be of value when FNA results are reported as 
benign, suspect or inadequate, although there are some limitations 
regarding its sensitivity. When FNA is reported as malignant, frozen 
section is unnecessary.84  
Lymph node dissection  
Gross cervical metastatic disease is treated by modified radical neck 
dissection, which results in excellent local control and minimal morbidity. 
Even though 80% of patients with PTC have occult cervical lymph node 
metastases most of these metastases can be ablated with radioiodine 
treatment postoperatively, and some does not appear to grow. Central 
compartment (medial to the carotid sheath) lymph nodes are frequent in 
word in patients with papillary, medullary and Hurthle cell carcinomas, and 
should be removed at the time of thyroidectomy, preserving the recurrent 
laryngeal nerves and parathyroid glands. Central Neck dissection is 
particularly important in patients with medullary and Hurthle cell 
carcinoma because of the high frequency of microscopic tumor spread and 
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because these tumors cannot be abalated with I131. An ipsilateral modified 
radical neck dissection is indicated in the presence of palpable cervical 
lymph nodes or prophylactically in patients with medullary carcinoma 
when the thyroid lesion is larger than 1.5 cm. Because contralateral 
lymph node metastases are uncommon (about 10%) a contralateral neck 
dissection is performed only when gross evidence of lymph node metastases is 
found. 
RADIOIODINE THERAPY114,115  
The postoperative treatment of patients with well differentiated thyroid 
cancer, particularly relating to radiotherapy, is some what controversial. I131 
ablation decreases tumor recurrence, development of distant metastases, and 
cancer death. Some studies have failed to detect an enhanced survival with 
the use of radio iodine ablation, particularly in low risk patients as defined 
by AMES criteria. 
Radioiodine therapy for locally advanced disease  
High ablative dose ranging from 100-150 mCi should be used in older 
age group, high risk patients such as those after an incomplete resection; an 
invasive primary tumor or distant metastases. The dose should deliver no 
more than 200 cGy to the blood, with no more than 120 mCi retained at 48 hrs 
or 80 mCi in the presence of pulmonary metastases. The most common side 
effects from radio iodine therapy include sialadenitis, nausea, and temporary 
bone marrow suppression. Testicular function and spermatogenesis are 
transiently impaired but appear to recover with time. There is a dose 
dependent in relationship between I131 therapy and the development of 
leukemia.  
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Radioiodine Therapy for Metastatic Disease  
Metastatic follicular cell derived thyroid carcinoma may concentrate 
iodine in upto 80% of cases, and TSH can stimulate this uptake. Treatment 
with I131 is therefore used widely to treat distant metastases, whether they are 
present at the time of original diagnosis or appear at a later time. There is 
shrinkage of pulmonary and other distant metastases after effective I131 
treatment because of the limited tissue penetration of the emitted beta 
particles. Prophylactic steroid administration may be helpful as the 
lesions tend to enlarge initially to form space occupying lesions. Bone 
metastases may require several modalities for adequate therapy. Surgery 
may be needed for orthopedic stabilization or palliation of pain.  
 
External radiation therapy  
Conventional radiation therapy may be detrimental to the success 
of radioiodine therapy in thyroid adenocarcinoma and should not precede 
therapeutic efforts with radio iodine. External radiation therapy in the 
management of thyroid cancer has been preserved for anaplastic carcinoma 
and lymphoma and differentiated cancer that does not concentrate 
radioiodine. Beneficial results with 35 to 70 Gy have been reported in the 
treatment of local recurrence in some differentiated cancers that did not take 
up radio iodine. In older patients with invasive papillary cancer and 
positive lymph nodes, 50-60 Gy external radiation significantly reduced the 10 
year recurrence rate.  
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Postoperative follow up  
  1. I131 whole body scan: Whole body scan is most sensitive when 
there is minimal remnant thyroid tissue. Tumours that are poorly 
differentiated, tumours in older patients and particularly Hurthle cell 
carcinoma may not concentrate iodine; this limits the usefulness of whole 
body thyroid scan. Patients stop using thyroid hormone 3 to 6 weeks before 
scanning to induce hypothyroidism. They are then administered tracer doses 
of I131, usually 1 to 3 mCi. These scans are repeated at regular intervals 
for duration depending on the risk of the patient.  
2. Serum thyroglobulin: Thyroglobulin is detectable in the serum in 
75% to 90% of healthy adults (normal levels-0 to30 ng/ml). After a total 
thyroidectomy, serum thyroglobulin is expected to be low or undetectable. The 
magnitude of thyroglobulin levels may be related to the tumour mass, degree 
of differentiation and the location of the metastases. A thyroglobulin level 
of 2 ng/ml or more in euthyroid patients and above 10 ng/ml in hypothyroid 
patients usually indicates recurrent differentiated thyroid carcinoma.104  
3.  Ultrasound:  Ultrasound is commonly used in the 
postoperative management of thyroid carcinoma to detect local or 
regional disease recurrence. Advantages include the ability to detect non-
palpable recurrent disease and the ability to perform a simultaneous USG-
guided FNA for diagnosis. It may be useful in patients in whom 
thyroglobulin measurement is not reliable.  
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4. Magnetic resonance imaging (MRI): MRI is sometimes used in 
the follow up of patients with differentiated thyroid carcinoma to detect the 
local or regional recurrence when serum thyroglobulin is elevated, and 
other testing like I131 whole body scan fail to localize disease recurrence.  
5. Positron emission tomography (PET): It is now clear that 
poorly differentiated carcinomas are much more likely to concentrate F18-
Fluorodeoxyglucose than I131. Hence the PET is found to be 50% to 85% 
sensitive in the localization of thyroid cancer that does not concentrate 
I131. Identification of these metastatic sites by FDG scanning may lead to 
significant alteration in the management of these patients.  
Postoperative thyrotropin suppression  
Suppression of TSH levels should be achieved with comparatively high 
doses of oral T4 continued for life, with attention to the potential thyrotoxic 
effects such as atrial fibrillation and cardiac compensation. Most 
investigators have reported an improved survival and lower recurrence 
rate in patients with TSH suppressive therapy.79 The standard dose 
prescribed after a total thyroidectomy is 0.1 to 0.2 mg daily. Failure of TSH 
suppression to a level <0.1 mU/L indicate an inadequate dose of thyroxine.  
B. Management of Anaplastic Carcinoma of the Thyroid  
Treatment results of anaplastic carcinoma are discouraging. Even 
under the most favorable circumstances and despite the employment of 
various aggressive treatment strategies that consists of surgery, 
radiotherapy, chemotherapy or a combination of all the three, almost all 
patients with the disease die a cancer-related death. Pathologically even a 
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focus of poorly differentiated or undifferentiated thyroid cancer in a 
background of well-differentiated cancer is believed to carry a prognosis 
similar to that of anaplastic cancer. The median survival of anaplastic thyroid 
cancer is 4 to 5 months, and a few patients have survived for a long 
term. After the possibility of anaplastic carcinoma is entertained based 
on history and physical examination, large core cutting needle biopsy will 
establish the diagnosis in most of the patients.  
The role of surgery is limited to the following: (a) open biopsy when 
needle biopsy fails to obtain enough tissue to differentiate anaplastic 
carcinoma from thyroid lymphoma and (b) securing the airway via 
tracheostomy. The most effective single cytotoxic drug is doxorubicin and in 
some patients this in combination with cisplatin has yielded a favorable 
response.88  
 
C. Management of medullary carcinoma of the thyroid  
The principal treatment advised for the patient with medullary 
carcinoma is surgery. Total thyroidectomy is the treatment appropriate for 
all cases irrespective of the primary tumour size. With improved early 
diagnosis by routine calcitonin measurement in nodular disease, occult 
medullary carcinoma of the thyroid has increasingly been observed. 
Considering the frequent involvement of central neck compartment in pT1 
carcinoma, an additional en bloc micro dissection central neck compartment 
is performed for accurate staging. In the presence of central lymph node 
metastases demonstrated by ultrasonography or demonstrated 
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intraoperatively, microdissection of both lateral compartments with 
curative intent is advocated because of frequent occurrence of lateral lymph 
node metastases in this setting.89  
If lymph node metastases are suspected in the upper mediastinum 
then a trans-sternal four-compartment lymphadenectomy is performed.. 
Patients with distant metastases at presentation usually have an 
unfavorable course that does not warrant extended surgery apart from 
total thyroidectomy, central lymphadenectomy and selective removal of 
symptomatic lymph nodes or tumour infiltrates. Radiation therapy is 
used as an adjuvant for patients with extensive soft tissue invasion or 
those with significant extra capsular extension in positive nodes after 
removal of all gross disease.90 It may also be considered for palliative control 
of inoperable disease.  
LYMPHOMA OF THE THYROID  
Thyroid lymphoma accounts for 1 % to 5% of all thyroid cancers 
and the incidence of lymphoma  is 2%  in  patients  undergoing  surgery  
for  thyroid malignancy.94 Thyroid lymphoma is a relatively rare disease 
constituting less than 1% of all lymphomas and accounting for 2% of extra-
nodal Non-Hodgkin‟s lymphoma.95 Most thyroid lymphomas develop in 
patients with chronic lymphocytic thyroiditis. Chronic antigenic lymphocytic 
stimulation has been suggested to result in lymphoma transformation. The 
most common presentation is that of a slowly growing thyroid mass, 
although approximately one third of the patients present with a more rapidly 
growing tumour. Patients usually present with symptoms similar to those 
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of anaplastic carcinoma and also with Type B symptoms in 20% of patients. 
Similar to patients with Hashimoto‟s thyroiditis these patients may present in a 
euthyroid, hypothyroid and occasionally even in hyperthyroid state. Open 
surgical biopsy is also indicated for the definite diagnosis or classification 
of lymphomas where FNA or core biopsy cannot provide sufficient 
information.92 Resection, chemotherapy and radiotherapy have an important 
role in the management depending on the stage of the disease.  
Sarcoma of the thyroid gland101  
Sarcoma of the thyroid gland is a rare neoplasm that may be 
confused pathologically with the spindle cell variant of anaplastic carcinoma 
of the thyroid.94 The treatment of sarcomas of thyroid is primarily surgical 
and consists of total thyroidectomy with excision of any locally involved 
tissue along with neck dissection for involved cervical nodes followed by 
postoperative radiotherapy is advocated for aggressive disease.  
Secondaries in the thyroid gland  
Although rare, secondary metastasis to the thyroid gland does 
occur, and accounts for about 1 % to 2% of all thyroid malignancies. The 
vascularity of the gland is thought to give rise to this phenomenon and Renal 
cell carcinoma has been the most common primary malignancy clinically.102 
Other observed primary tumour sites include lung, breast, melanoma and 
head and neck tumors. Secondary metastases to the thyroid signify a very 
poor prognosis. Some patients present with occult primary tumour.  
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OBJECTIVES 
 
The objectives of this study include the following:- 
 
1. To study the age and gender incidence of Thyroid carcinoma. 
2. To study the various clinical presentations of thyroid carcinoma in 
relation to the various pathological types of thyroid carcinoma. 
3. To study the role of the Fine Needle Aspiration Cytology (FNAC) in the 
diagnosis of the thyroid carcinoma. 
4. To study the clinical characteristics of the histological variants of the 
papillary and follicular thyroid carcinoma. 
5. To study the role of the radiological investigations in the evaluation of 
the Thyroid carcinoma. 
6. To study the correlation between the size of the thyroid carcinoma to the 
various morphological characteristics of the thyroid carcinoma 
7. To study the surgical management in the Thyroid carcinoma.  
8. To study the immediate post operative complications of thyroid surgeries 
in cases of Thyroid carcinoma. 
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METHODOLOGY 
 
STUDY AREA:  
This study was conducted in the Department of General surgery and 
Department of Surgical Oncology in Madurai Medical College and Government 
Rajaji Hospital, Madurai. 
 
STUDY PERIOD:  
  It was two years duration and the data collected during the period from 
June 2010 to May 2012. 
 
SOURCE OF DATA: 
This is a retrospective study done in the Madurai Medical College and 
Government Rajaji Hospital, Madurai. The data was collected regarding Thyroid 
carcinoma from all the cases diagnosed and treated for Thyroid Carcinoma with 
histological evidence. The details after collecting from the Medical Records 
Department of Government Rajaji Hospital were entered and evaluated in the 
proforma (ANNEXURE -2). The institute ethical committee clearance was 
obtained for this study. 
SAMPLE SIZE 
 The total number of cases that were included in the study was 60 in 
number as per the criteria.  
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INCLUSION CRITERIA: 
1. Cases diagnosed as Thyroid Carcinoma with histological diagnosis from 
the case sheets diagnosed as Thyroid Carcinoma and admitted in the hospital, 
from the Medical Records Department of Madurai Government Rajaji Hospital 
with age 13 years and above during the period from June 2010 to May 2012.  
2. Patients who were operated previously for benign conditions of thyroid 
and diagnosed as Carcinoma of thyroid at present in the study period 
 
EXCLUSION CRITERIA: 
1. Patients below 12 years of age. 
2. Patients who were clinically diagnosed as Thyroid carcinoma and without 
any histological diagnosis on subsequent evaluation.   
3. Patients diagnosed as Thyroid carcinoma clinically and post operative 
specimen turned out to be benign lesion. 
4. Patients who were not willing for any treatment after the diagnosis were 
excluded from the study. 
5. Patients who were operated previously for carcinoma of thyroid with 
recurrence in this study period excluded. 
6. Patients who discontinued the treatment during the study period were 
excluded.  
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METHODS OF COLLECTION OF DATA:  
 
 A Proforma for study of all the patients of carcinoma thyroid was used. 
The presentation, clinical findings, investigations and line of 
management were documented in the proforma.   
     All cases of thyroid carcinoma underwent pre operative ultrasonography 
of the thyroid and the lateral neck and were preceded for FNAC based on 
the sonographic features and the clinical features. The sonographic lesions 
found were solid nodules, mixed cystic-solid nodules, spongiform nodules, 
simple cyst. The sonographic features considered as suspicious for 
malignancy include hypo echoic lesions, micro calcifications, increased 
central vascularity, infiltrative margins and the lesions taller than wide in the 
transverse plane. 
 
    The sonographic features and clinical features suggesting malignancy of 
the thyroid lesions underwent FNAC for diagnosis in all the sonographic 
lesions except in simple cystic lesions.  
o If FNAC report shows papillary carcinoma or features suggestive 
of papillary carcinoma were proceeded for total Thyroidectomy 
and prophylactic central compartment neck nodal dissection of 
Total Thyroidectomy with comprehensive neck dissection if nodes 
are palpable or suspicious nodes found in the ultrasound of the 
lateral neck. 
o If FNAC report shows “Follicular of Hurthle cell neoplasms”, Total 
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thyroidectomy was done in cases of invasive cancer and 
metastatic cancer or the patients preferring total thyroidectomy 
and in all other cases hemithyroidectomy was done initially and 
the post operative histopathology showing follicular 
carcinoma/Hurthle cell carcinoma, completion of the 
thyroidectomy was done and comprehensive neck dissection was 
done if the neck nodes were found clinically and radiologically. 
o If FNAC report describes the lesion as, “Follicular lesion of 
undetermined significance, the lesions underwent repeat FNAC 
and was preceded for the surgery based on the cytology report, 
sonographic features and clinical features. 
o If FNAC report shows Thyroid lymphoma, they were preceded 
accordingly. 
o If FNAC report shows, “Insufficient biopsy, non diagnostic” and it 
is solid lesion by Sonography, they were succumbed to repeat 
FNAC and proceeded accordingly.  
     The patients were referred for higher centre for the post operative 
radioiodine evaluation and the treatment.  
STATISTICAL TESTS  
  The statistical tests used in this study are the test of proportion and 
percentage. 
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RESULTS 
Age and gender incidence: 
The incidences of thyroid carcinoma among the various age groups 
were calculated. (Table 1, Fig.1.). It was found that the commonest age 
group belongs to the fourth followed by fifth and second decades of life. 
Table. 1: Age Incidence in Thyroid Malignancies in our study group 
of 6o patients. 
Age in years 
Total No. of 
Cases 
Percentage (%) 
13–19 2 3.3 
20 -29 12 20 
30-39 22 36.7 
40-49 12 20 
50-59 4 6.7 
60-69 4 6.7 
70-79 4 6.7 
Total 60 100 
 
Fig. 1: Age Incidence in thyroid carcinoma in our study group of  
               60 patients. 
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The histological variants of thyroid carcinoma in relation to the age 
distribution are depicted in Table 2 and Fig.2.  
 
Table 2: Age distribution in relation to the histological variants of  
               thyroid carcinoma 
Age in years Papillary Follicular Anaplastic 
13–19 2 0 0 
20 -29 10 2 0 
30-39 18 4 0 
40-49 9 3 0 
50-59 2 2 0 
60-69 3 0 1 
70-79 4 0 0 
Total 48 11 1 
 
Fig. 2: Age distribution in relation to the histological variants of 
thyroid carcinoma. 
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The gender incidence in thyroid carcinoma in relation to the histological 
variants of Thyroid Carcinoma in our study is depicted in Table 3 and Fig. 3. 
 
Table 3: Gender incidence in relation to the histological variant of  
               Thyroid Carcinoma in the study. 
 
 
Histological Variant Females Males Total 
Papillary Carcinoma 40 8 48 (80%) 
Follicular Carcinoma 9 2 11 (18.33%) 
Anaplastic Carcinoma 1 0 1 (1.67%) 
Medullary Carcinoma 0 0 0 
Lymphoma 0 0 0 
Total 50 10 60 
 
Fig. 3. Gender incidence in relation to the histological variant of  
            Thyroid Carcinoma in the study. 
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Table 4: Clinical symptoms found in this study group. 
 
S. No. Symptoms No. of. cases Percentage 
1 Thyroid Swelling 57 95 
2 Lymph Nodal Swelling 10 16.33 
3 Hoarseness of Voice 6 10 
4 Dysphagia 3 5 
5 Dyspnea 3 5 
6 Symptoms of Hyperthyroidism 1 1.33 
7 Distant Metastasis 5 8.13 
 
 
Fig 4: Clinical features found among the 60 cases in the study. 
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In our study group, it was found out to be that the patients 
predominantly presented with the enlargement of thyroid in 95% of the cases 
followed by the lymph nodal swelling in ten cases of which 3 cases had only 
lymph node swelling without any thyroid enlargement. The most common 
pressure effect found in our study group is hoarseness of voice in six patients 
clinically followed by dyspnea and dysphagia in three patients each. The 
results are depicted in Table 4 and Fig.4. 
Thyroid Profile: 
     The thyroid profile done in all the patients which did not show any 
features of hypo or hyperthyroidism except one patient who had diagnosis of 
papillary carcinoma. 
Indirect Laryngoscopy: 
    Indirect laryngoscopic examination was done preoperatively in all the 
patients revealed vocal cord palsy in eight of them of which six patients had 
hoarseness of voice clinically. Six patients were diagnosed to be of papillary 
carcinoma of thyroid and one case found out to be follicular carcinoma and 
the other being the case of anaplastic carcinoma.  
Duration of the thyroid swelling: 
The duration of the swelling are depicted in the Table 5 and Fig.5. 
Predominantly they present with symptoms duration less than three months 
followed by duration between three to six months.  
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Table. 5: Duration of the Thyroid swelling in the 60 patients. 
Duration of the 
swelling 
Number of the Cases Percentage 
<  3 months 17 28.33% 
3-6 months 12 20 % 
6 – 12 months 12 20% 
1- 3 years 10 16.33% 
3- 5 years 4 6.67% 
5 – 10 years 2 3.33% 
> 10 years 0 0 
  
 
 
Fig. 5: Duration of the Thyroid Swelling in the study group 
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Results of the FNAC diagnosis:  
 The results of the FNAC showing papillary carcinoma or suspicious for 
papillary carcinoma in 45 cases, Follicular/Hurthle cell neoplasms in 6 cases, 
Follicular cells of undetermined significance in 4 cases, anaplastic carcinoma 
in a case and non diagnostic in 4 cases. Eight cases which revealed 
cytological report as “Follicular cells of undetermined significance” and “Non 
diagnostic” were subjected to sonographic guided FNAC of which three cases 
showed diagnosis of papillary carcinoma and preceded accordingly and three 
cases showed follicular/Hurthle cells and were preceded accordingly, whereas 
two cases did not have any cytological diagnosis even after repeat FNAC and 
were subjected to hemithyroidectomy in a case and total thyroidectomy in the 
other case based on the clinical and sonographic features. 
 
Table 6: Reports of the FNAC in this study: 
 
FNAC diagnosis Males Females Total 
Papillary carcinoma or 
suspicious for Papillary 
carcinoma 
7 38 45 
Follicular/Hurthle cell 
Neoplasms 
1 5 6 
Follicular cells of 
Undetermined significance 
1 3 4 
Medullary Carcinoma 0 0 0 
Anaplastic Carcinoma 0 1 1 
Non diagnostic 1 3 4 
Total 10 50 60 
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Of the Four cases which showed diagnosis of Follicular/Hurthle cell 
neoplasms, two cases were subjected to total thyroidectomy based on 
sonographic features of invasion and two cases subjected to 
hemithyroidectomy and diagnosed as follicular carcinoma and were subjected 
to the completion of thyroidectomy. The results are depicted in Table 6 and 
Fig.6. 
 
Fig.6. Reports of the Fine needle aspiration cytology in this study. 
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Ultrasonographic findings: 
 Sonography was done in all the patients and the findings suggestive of 
the malignancy in the ultrasonography was found and compared in Table 7 
and Fig.7. There were hypoechogenic nodules found in 47 cases in total, 
irregular margins in 37 cases and fine punctuate internal calcifications found 
in 35 cases and the features in total were compared. Also sonogram identified 
nodes in 13 cases which were not palpable clinically. And CT of the neck was 
done in the cases with bulky tumours, or tumours with retrosternal extension, 
but not routinely done in all cases. Invasion of the tumour was found in 21 
cases in total and of those 18 cases were papillary carcinoma and 3 cases 
were of follicular carcinoma in this study. 
 
Table 7: Ultrasonographic findings found preoperatively in the cases 
of thyroid carcinoma in this study. 
 
Findings on Ultrasonogram 
Papillary 
Carcinoma 
Follicular 
Carcinoma 
Solid/hypoechogenic nodule 39 8 
Heterogenous echogenic structure 9 2 
Irregular margins 33 4 
Extraglandular extension 18 3 
Fine punctuate internal calcifications 33 2 
Suspicious nodes 22 4 
Tracheal infiltration 1 - 
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Figure 7: Ultrasonographic findings found pre operatively in the 
cases of Thyroid carcinoma in this study. 
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Size of the thyroid swelling: 
The clinical and radiological size of the thyroid nodule suspicious of 
malignancy was found and they were correlated with the incidence of lymph 
node metastasis, as we know that the diameter of the tumour is an independent 
prognostic factor and the association between them is found. We found out that 
cases predominantly were present between 2-6 cm in diameter and the details 
are depicted in the Table 8 and Fig.8. 
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Table 8: Diameter of the tumour in relation to the histological variants 
found in this study. 
Diameter of 
the tumour 
No. of cases of 
Papillary 
carcinoma(%) 
No. of cases of 
follicular 
carcinoma(%) 
Total. 
No. of 
cases 
0-1cm 5 0 5 
1-2cm 8 1 9 
2-4cm 12 3 15 
4-6cm 12 4 16 
6-8cm 7 1 8 
> 8cm 4 2 6 
Total 48 11 59 
 
Fig. 8: Diameter of the tumour in the histological variants found in this 
study. 
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Lymph Node metastasis found among the histological variants of the 
thyroid carcinoma in the study. 
 
  The incidence of lymph node metastasis between the histological variants 
of thyroid carcinoma was found and analyzed in Table 9 and Fig.9. In total 26 
cases of lymph node metastasis was found clinically and of those, 22 cases had 
papillary carcinoma as the histological variants and 4 cases had follicular 
carcinoma. 
Table 9: No. of cases of the lymph node metastasis found among the 
histological variants of thyroid carcinoma. 
 
Histological variant 
No. of 
cases 
No. of. Cases 
with nodal 
metastasis 
Percentage of 
nodal 
metastasis 
Papillary carcinoma 48 22 45.83% 
Follicular carcinoma 11 4 36.36% 
Anaplastic Carcinoma 1 0 0 
Total 60 26 43.33% 
 
Fig. 9: No. of cases of the lymph node metastasis found among the 
histological variants of thyroid carcinoma. 
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Distant metastases found among the histological variants of the 
thyroid carcinoma: 
     There were five cases of thyroid carcinoma with the distant metastasis in the 
study. Of the five cases, three cases belong to the papillary carcinoma and two 
cases belong to the follicular carcinoma and are depicted in Table 10 and Fig.10. 
Table 10: No. of cases of distant metastases in relation to the histology 
of the thyroid carcinoma in this study. 
Site of Metastasis Papillary carcinoma Follicular carcinoma 
Bony metastasis (Rib) 1 - 
Bony metastasis ( Mandible) - 1 
Multiple Bony metastasis to 
rib, mandible, skull 
- 1 
Pulmonary metastasis 2 - 
Total 3 2 
Incidence of distant 
metastasis in percentage 
6.25% 18.2% 
 
Fig.10: No. of cases of distant metastases in relation to the histology of 
the thyroid carcinoma in this study. 
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Papillary carcinoma and its variants: 
 
 Out of 48 cases of papillary carcinoma in our study, 33 cases were found 
out to be of classical papillary carcinoma, 10 cases were follicular variant of 
papillary carcinoma, 3 cases were columnar cell variant of papillary carcinoma 
and two cases were tall cell variant of papillary carcinoma and are depicted in 
Table 11 and Fig.11. 
Table 11: Papillary carcinoma and the histological variants found in the 
study.  
Histological variants Number of the cases Percentage 
Classical Papillary carcinoma 33 68.75% 
Follicular variant 10 20.83% 
Columnar cell variant 3 6.25% 
Tall cell variant 2 4.17% 
Total 48 100% 
 
Fig.11. Papillary carcinoma and the histological variants found in the 
study. 
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Age, Gender and clinical features of the individual histological 
variants of the papillary carcinoma of the thyroid. 
 
       The various individual histological variants of the papillary carcinoma were 
compared and analyzed in Table 12.  
 
Table 12: Comparison of the age, gender and clinical features of the 
individual histological variants of the papillary carcinoma of the 
thyroid. 
 
 
Classical 
Variant 
Follicular 
variant 
Columnar 
variant 
Tall cell 
variant 
No. of. cases 33 10 3 2 
Mean age 37 33 46 53 
Female : Male 6:1 9:1 2:1 1:1 
Lymph node 
metastases 
17 3 2 2 
Distant 
Metastases 
2 1 - - 
 
 
The classical papillary carcinoma shows mean age at diagnosis of 37 
years whereas the follicular variant of papillary carcinoma showed mean age at 
diagnosis of 33 years, followed by columnar variant of 46 years of age and the 
tall cell variant of 53 years of age. There was also significant difference in the 
gender incidence and clinical features of the individual variants which are 
depicted in Table 12. Also there is relatively decreased incidence of the lymph 
node metastases found in the Follicular variant of papillary carcinoma in this 
study. 
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Comparison of the diameter of the tumour with the various 
morphological parameters in our study. 
 
 We compared the diameter of the tumour and the histological variants 
with the various morphological parameters viz., the multifocality, the invasion of 
the tumour, the risk of the lymph node metastases, and the risk of the distant 
metastases and statistically correlated. The results are depicted in the table 13, 
14, 15, 16, 17 and were statistically analyzed. 
 
Table. 13: Comparison between the diameter of the tumour and the 
multifocality of the tumour. 
 
Diameter 
of the 
tumour 
Papillary 
Carcinoma 
Follicular 
Carcinoma 
All cases of 
Thyroid 
Carcinoma 
N
o
. 
o
f 
c
a
s
e
s
 
M
u
lt
if
o
c
a
li
ty
 
%
a
g
e
 
N
o
. 
o
f 
c
a
s
e
s
 
M
u
lt
if
o
c
a
li
ty
 
%
a
g
e
 
N
o
. 
o
f 
C
a
s
e
s
 
M
u
lt
if
o
c
a
li
ty
 
%
a
g
e
 
0-1cm 5 1 20.00 0 - 0 5 1 20.00 
1-2cm 8 2 25.00 1 - 0.00 9 2 22.22 
2-4cm 12 2 16.67 3 - 33.33 15 2 20.00 
4-6cm 12 4 33.33 4 1 25.00 16 5 31.25 
6-8cm 7 2 28.57 1 1 0.00 8 3 25.00 
> 8cm 4 2 50.00 2 1 50.00 6 3 50.00 
Total 48 13 27.08 11 3 27.27 59 16 27.12 
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There were 13 cases of papillary carcinoma with multifocal carcinoma 
and three cases of follicular carcinoma with multifocality as depicted in the Table 
13 and Fig.12. Follicular carcinoma has increased incidence of multifocality 
surprisingly as the tumour size increases over 4 cm but the statistical correlation 
could not be found due to less number of cases in follicular carcinoma. There 
was weak statistical correlation between multifocality in papillary carcinoma and 
the diameter of the tumour once the diameter of the tumour increases above 4 
cm. (“P” value- 0.03). One case which had only nodal metastases and on total 
thyroidectomy specimen showed multifocality without any clinical evidence of 
thyromegaly. 
Fig. 12: Comparison between the diameter of the tumour and the 
occurrence of the multifocality of the tumour. 
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The diameter of the tumour and the incidence of extra thyroidal 
extension among the histological variants of the thyroid carcinoma in this study 
was compared and analyzed in Table.14 and Fig.13. There was statistically 
correlation found between the diameter of the tumour and extra thyroidal 
extension in cases of papillary carcinoma as the diameter of the tumour 
increases. But there was no clear cut statistical association found in the follicular 
carcinoma between diameter of the tumour and the extra thyroidal extension.  
 
Table 14: Comparison between the diameter of the tumour and the 
occurrence of the extra thyroidal extension. 
 
Diameter 
of the 
tumour 
Papillary 
Carcinoma 
Follicular 
Carcinoma 
All cases of 
Thyroid 
Carcinoma 
N
o
. 
o
f 
c
a
s
e
s
 
E
x
tr
a
 
T
h
y
ro
id
a
l 
e
x
te
n
s
io
n
 
%
a
g
e
 
N
o
. 
o
f 
c
a
s
e
s
 
E
x
tr
a
 
T
h
y
ro
id
a
l 
e
x
te
n
s
io
n
 
%
a
g
e
 
N
o
. 
o
f 
C
a
s
e
 
E
x
tr
a
 
T
h
y
ro
id
a
l 
e
x
te
n
s
io
n
 
%
a
g
e
 
0-1cm 5 0 0.00 0 0 0.00 5 0 0.00 
1-2cm 8 2 25.00 1 0 0.00 9 2 22.22 
2-4cm 12 5 41.67 3 1 33.33 15 6 40.00 
4-6cm 12 6 50.00 4 1 25.00 16 7 43.75 
6-8cm 7 3 42.86 1 1 100.00 8 4 50.00 
> 8cm 4 2 50.00 2 0 0.00 6 2 33.33 
Total 48 18 37.50 11 3 27.27 59 21 35.59 
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Fig. 13: Comparison between the diameter of the tumour and the 
occurrence of the extra thyroidal extension. 
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The lymph node metastasis was correlated with diameter of the tumour 
in relation to the histological variants of the thyroid carcinoma and is depicted in 
Table 15 and Fig.14. There were three cases of isolated lymph node metastases 
without any thyromegaly. There was strong statistical correlation found between 
the diameter of the tumour and the incidence of the lymph node metastases 
above 2 cm in papillary carcinoma and above 4 cm in follicular carcinoma as the 
diameter of the tumour increases. The correlation between the diameter of the 
tumour and the distant metastases is depicted in Table 16 and Fig.15 but there 
was no statistical correlation found between the two parameters in this study. 
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Table 15: Comparison between the diameter of the tumour and the 
occurrence of the lymph node metastasis. 
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1-2cm 8 1 12.5 1 0 0 9 1 11.11 
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4-6cm 12 8 66.67 4 2 50 16 10 62.5 
6-8cm 7 4 57.14 1 1 100 8 5 62.5 
> 8cm 4 2 50.00 2 1 50 6 3 50.00 
Total 48 22 45.83 11 4 36.36 59 26 44.07 
 
Fig 14: Comparison between the diameter of the tumour and the 
occurrence of the lymph node metastases in this study. 
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Table 16: Comparison between the diameter of the tumour and the 
occurrence of the distant metastasis in this study. 
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0-1cm 5 - 0.00 0 - 0.00 5 - 0.00 
1-2cm 8 - 0.00 1 - 0.00 9 - 0.00 
2-4cm 12 1 8.33 3 - 0.00 15 1 6.67 
4-6cm 12 1 8.33 4 1 25.00 16 2 12.50 
6-8cm 7 - 0.00 1 1 100.00 8 1 12.50 
> 8cm 4 1 25.00 2 - 0.00 6 1 16.67 
Total 48 3 6.25 11 2 18.18 59 5 8.47 
 
Fig. 15: Comparison between the diameter of the tumour and the 
distant metastasis in this study. 
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Table 17: Statistical correlation comparing the various morphological 
parameters comparing the diameter of the tumour in the papillary and 
follicular carcinomas in our study group. 
 
S.No. Parameters 
‘P’  Value 
Papillary 
carcinoma 
Follicular 
carcinoma 
1. Comparison between the diameter of 
the tumour and the multifocality 
0.02 0.3 
2. Comparison between the diameter of 
the tumour and the extra thyroidal 
extension 
.01 0.001 
3. Comparison between the diameter of 
the tumour and the lymph node 
metastasis 
<0.0001 0.001 
4. Comparison between the diameter of 
the tumour and the distant 
metastasis 
0.26 0.35 
 
 
The statistical correlation was found between the diameter of the tumour 
and the multifocality, extra thyroidal extension and lymph node metastasis in 
papillary carcinoma and the „P‟ value found to be 0.02, 0.01 and <0.0001 
respectively and in cases of follicular carcinoma there was statistical correlation 
found between the diameter of the tumour and the extra thyroidal extension 
and „P‟ value found to be 0.001 in both the cases. There was no statistical 
correlation found between the diameter of the tumour and the distant 
metastases and the results are depicted in the Table 17 mentioned above. 
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Table 18: AJCC TNM- 2010 staging of thyroid malignancies in the 
study group of 60 patients. 
 
Staging 
Papillary 
carcinoma 
Percentage Follicular cell 
carcinoma 
Percentage 
Stage I 36 75.0% 5 45.4% 
Stage II 3 6.3% 2 18.2% 
Stage III 3 6.3% 2 18.2% 
Stage IVA 2 4.1% 1 9.1% 
Stage IVB 3 6.3% -- 0.0% 
Stage IVC 1 2.0% 1 9.1% 
Total 48 100% 11 100% 
 
 
Fig. 16: AJCC TNM 2010 staging of thyroid malignancies in the study 
group of 60 patients. 
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Most of the cases of the papillary carcinoma found to be Stage I (75%) 
and 45% of cases in the follicular carcinoma and are depicted in the Table 18 
and Fig.16. 
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Table 19: Details of the surgery performed for the primary disease in 
this study. 
 
Surgery No. of Cases 
Total Thyroidectomy 47 
Hemithyroidectomy followed by completion thyroidectomy 4 
Near total thyroidectomy 7 
Hemithyroidectomy 1 
 
 
 
Figure 17: Details of the surgery performed for the primary disease. 
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The most commonly performed surgery in the study was total 
thyroidectomy. Forty seven patients underwent total thyroidectomy. The four 
patients, whose cytology turned out to be follicular/Hurthle cells and with a 
solitary nodule underwent hemithyroidectomy and later a completion 
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thyroidectomy after the histopathological report had turned out to be 
follicular carcinoma. Five patients whose  cytology showed, “ Follicular 
cells of undetermined significance” and clinically showing multi nodular 
goiter and solitary nodular goiter with radiological findings suggestive of 
high possibility of malignancy underwent total thyroidectomy as the 
surgery for the primary procedure. Eight of the patients in the study had 
infiltration of the recurrent laryngeal nerve by the tumour and seven 
patients underwent a near-total thyroidectomy leaving minimal thyroid 
tissue adjoining the recurrent laryngeal nerve and other patient being 
anaplastic carcinoma was treated with external beam radiotherapy. 
 
Surgery for Nodal Secondaries: 
12 patients who had Level VI nodes clinically and radiologically were 
succumbed to central compartmental neck dissection and 16 patients who had 
cervical lymphadenopathy clinically and radiologically suspicious of malignancy 
in the Level II-V group of lymph nodes were subjected to functional neck 
dissection for level II, III and IV group of cervical lymph nodes and are 
depicted in Table 20 and Fig.18. The case with anaplastic carcinoma was 
subjected to External Beam Radiotherapy. One case which had a small lesion 
less than 1 cm underwent only hemithyroidectomy and did not undergo any 
neck dissection. Five cases without any nodal secondaries but with high risk 
features were subjected to Prophylactic central compartment neck dissection in 
addition to total thyroidectomy. The central compartment neck dissection 
included removal of pre tracheal, para tracheal and pre laryngeal nodal tissues. 
Other cases without any nodal secondaries and also with low risk features were 
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not subjected to any prophylactic central compartment neck dissection and 
were referred for radioactive iodine scanning for the residual disease. In total 
33 cases were subjected to either central compartmental/lateral neck dissection 
in addition to the total thyroidectomy. 
Table 20: Details of the patients who underwent neck dissection in 
this study. 
 
Type of Neck Dissection No. of cases 
MRND and central compartmental Neck dissection 16 
Central Compartmental Neck Dissection 12 
Prophylactic central Compartmental Neck 
dissection 
5 
Total  33 
 
 
Figure 18: Number of patients underwent neck dissection in this 
study. 
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Risk Categorization  
  Among the 60 patients the study 59 patients had well 
differentiated carcinomas of follicular cell origin. These patients were 
categorized into low and high risk groups based on the AMES categorization 
scheme.   
 
Table 21: AMES categorization scheme for well-differentiated 
Carcinomas in this study. 
 
Type Low-risk High-risk 
Papillary carcinoma 14 34 
Follicular carcinoma 4 7 
Total 18 41 
 
 
Fig. 19: AMES categorization scheme for well-differentiated 
                  Carcinomas 
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When all patients with well-differentiated thyroid carcinomas were 
considered 30% of the patients were of the “low-risk” category and 70% were 
of the “high-risk” category. If patients with papillary thyroid carcinomas are 
alone considered 84% are of “high risk” and 20% are of “low risk” 
categories.  
 
Complications of Surgery: 
All the patients were observed in the immediate post-operative 
period. The patients underwent indirect laryngoscopy in case they complain 
of hoarseness of voice, and the serum calcium was estimated if the 
Trousseau‟s sign (inducing carpo pedal spasm by occlusion of the arm with a 
blood pressure cuff for 3 minutes) was positive.  
 
Table 22: Complications of surgery found in this study after operated 
for thyroid carcinoma. 
Complication Number of cases 
Transient hypo parathyroidism 7 
Recurrent laryngeal nerve palsy 2 
 
All symptomatic hypocalcaemia patients were treated with 10 ml 
of 10% calcium gluconate slow i.v. less severe cases were treated 
with oral calcium supplements along with vitamin D. All the patients 
recovered in the immediate postoperative period. Two patients out of 52 
patients who had normal vocal cord status preoperatively suffered recurrent 
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laryngeal nerve palsy postoperatively and the remaining 8 patients who 
underwent near total thyroidectomy since they had pre operative unilateral 
vocal cord palsy did not have any additional vocal cord palsy. None of the 
patients had wound infection.  
Among the patients who came for regular follow up none of the 
patients developed hypocalcaemia on a long term.  
 
Postoperative Advice  
All the patients with differentiated thyroid carcinomas were referred to 
higher centers for radioiodine therapy and follow up. One patient who 
had anaplastic carcinoma was advised to undergo external beam 
radiotherapy. All patients were started on the thyroxine suppressive therapy 
postoperatively.  
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DISCUSSION 
 Dave RI et al. (1983) and Basali et al. (1979) have studied the age 
incidence of thyroid carcinoma and have reported that the commonest age 
group affected is the 5th and the 6th decade respectively105, 106.  In our study, 
cases in the 4th decade & 5th decade of life followed by third decade are 
commonly affected.   As we know, age at diagnosis is one of the important 
parameters that affect the prognosis. The mean age at the diagnosis is 49 years 
in the western studies and in our study group it was found to be 38 years.  
 
The study conducted in England and Wales in 1993 to know the sex 
ratio of hormone dependant cancers by Dos Santos Silva and Swerdlow 
showed that thyroid cancer is predominantly seen in women in a ratio of 3:1.22 
In the present study the sex ratio of thyroid malignancies is found to be 5:1. 
Even though females have an increased incidence of thyroid cancer, males 
demonstrate a poorer prognosis after diagnosis of the disease. The presence of 
large (greater than 5 cm) tumors doubles in the males. Males have high 
propensity to metastasize, both to regional nodes and distally. Mitchell et al. 
found that males were more likely to have advanced stage tumors at diagnosis. 
These factors, combined with the age at which men develop thyroid cancer, 
contribute to higher mortality rates among the male gender (7.1%) compared 
to women (3.5%). In our study we didn‟t find any significant difference 
between genders in the stage specific incidence between the groups which can 
be due to the less number of cases in the male gender.  
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The most plausible theory for the cause of the gender distinctions, 
however, is the hypothesis that the female sex hormones, primarily estrogen, 
play a role in the pathology of thyroid carcinoma and consequent to the 
finding, estrogen has become a major target for new therapy research in 
thyroid cancer. The supportive evidence for the estrogen theory is the decrease 
in incidence for females after menopause. In future, the molecular therapy 
targeting the estrogen receptor could become a new mode of treatment and 
possibly prophylaxis for thyroid carcinoma in high risk familial cases, but 
extensive studies looking at into these molecular issues are needed. Also we 
found difference in the mean age of incidence between the histological variants 
of the papillary carcinoma. 
 
Table 23: Gender incidence of thyroid malignancies – Comparison. 
 
Gender Dos Santos Silva et al.22 Our study 
Female:Male ratio 3:1 (74.1:25.9) 5:1 
 
 
 Clinical features that give rise to suspicion of malignancy include nodules 
at the extremes of age, male gender, hard consistency, fixation to the 
surrounding structures, and size of the tumour greater than 4 cm, rapid growth 
and a solitary nodule, a history of exposure to radiation in childhood. The most 
important finding suggestive of malignancy is implied by the presence of cervical 
lymphadenopathy. 
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The predominant symptom in the present study was thyroid mass 
which was also the predominant symptom in the study conducted by Simon 
Holzer et al.106 in 1996 in Germany and published in 2000; which was also the 
predominant symptom in Kannan RR108 study of 670 Cases of carcinoma 
thyroid from 1956 to 1996 in cancer institute, Madras.  
 
Thyroid carcinoma is known for its variability in the presentation ranging 
from the solitary thyroid nodule, multi nodular thyroid and also the isolated 
lymph node metastases without any thyroid swelling. The distant metastases 
found in our study were five out sixty patients. The hoarseness of voice in this 
study was due to the recurrent laryngeal nerve involvement which was found in 
eight of the patients and all were unilateral. The documentation of the vocal 
cord status using indirect laryngoscopic examination preoperatively is 
mandatory and all cases of thyroid carcinoma need to be carefully looked up 
even if they are not symptomatic. Vocal cord palsy was higher among the locally 
invasive tumours particularly anaplastic carcinoma and papillary carcinoma. 
 
The percentage of patients presenting with dysphagia and dyspnea are 
very much less (6% each) compared to the study by Simon et al.106 (25% and 
10.5%). 8.33% of patients presented with distant metastases compare to 
12% in Kannan RR107 study. 
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Table 24: Clinical features of thyroid malignancies – Comparison 
between the studies. 
Symptoms Simon et al.106 Kannan RR107 Present study 
Thyroid swelling 77% 84% 95% 
Lymph nodal mass 5.6% 42% 16.67% 
Hoarseness of voice 4.6% 14% 13.33% 
Dysphagia 25% 8.9% 5% 
Dyspnoea 10.5% 3% 5% 
Distant metastases 0 12% 8.33% 
 
 
Figure 20: Clinical features of thyroid malignancies – Comparison 
between the studies. 
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Thyroid carcinoma patients do not present with thyroid 
dysfunction commonly as numerous studies show hyperthyroidism in 1-
2% of patients and in our study only one patient had features of 
hyperthyroidism that had solitary thyroid nodule and was managed 
accordingly. 
 As we know the course of the thyroid carcinoma can vary from the 
indolent course to slow growing tumour and to aggressive growth 
depending upon the type of the histological variants, and the type of 
malignancy and also depends upon the gender and the mode of 
presentation of the tumour. In our study, 70% of the cases present in 
the duration less than one year and 30% of cases have more than 12 
months of history of the thyroid swelling which depicts the slow growing 
nature of thyroid carcinoma. Three of the cases who had only lymph 
node metastasis have varied duration of the history. Many patients have 
the tendency to present later to the physician owing to the low socio 
economic status, ignorance of the disease. 
 
Cytological examinations by FNAC play an important role in the diagnosis 
of thyroid carcinoma in Solitary thyroid nodules. As per the NCI‟s state of the 
science conference held in 2007, FNA diagnosis from the FNA specimen is 
typically categorized into six types as described earlier. Although FNAC is 
sensitive, false negative results are common and FNAC needs to be repeated if 
concerning features found in the clinical features and/or sonographic features. 
Molecular diagnosis of mutations in BRAF, RET, or RAS patterns in the FNAC 
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samples that are indeterminate (Follicular/Hurthle cells of follicular cells of 
undetermined significance) but it is not commonly done due to the unavailability 
of the molecular tests in routine clinical practice. In our study, FNAC was found 
to be useful in diagnosis of thyroid carcinoma. FNAC was repeated in cases 
where the initial FNAC report which came as non diagnostic or follicular cells of 
undetermined significance. FNAC could not differentiate benign and malignant 
follicular lesions. The sensitivity of FNAC could not be found out in this study. 
 
 In the present study the papillary carcinoma was the most common 
type of thyroid malignancy seen in the hospital accounting for about 80 
percent of the cases. In the study conducted by Simon et al.,106 papillary 
thyroid carcinoma formed about 66.4% of the study. The proportions of 
different types of thyroid malignancies in the present study are similar to 
those in the study conducted by Simon et al.106. 
  
Among the follicular cell carcinoma, Hurthle cell carcinoma occurred in 
three cases and they have high metastatic potential than the follicular cell 
carcinoma and hence they are considered as the separate entity in the 
treatment guidelines different from the follicular cell carcinoma. In our study 
we found three cases of Hurthle cell carcinoma which had high incidence of 
lymph node and the distant metastasis than the follicular cell carcinoma. 
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Table 25: Various types of thyroid malignancies in different studies – 
Comparison  
Type Simon et al.106 Scott et al.108 Present study 
Papillary 66.4% 81% 80% 
Follicular 27.2% 13.6% 18.33% 
Anaplastic 3.6% 1.7% 1.67% 
Medullary 2.8% 3.2% 0 
 
 
Figure 21:  Various types of thyroid malignancies in different studies -             
                    Comparison  
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There are numerous histo pathologic variants of Papillary carcinoma of 
thyroid and each variant shows a combination of specific growth patterns, cell 
types and stromal changes histologically and the criteria used to define these 
subtypes are not rigorously defined which leads to inter observer variations. 
 
  81 
In our study we found 30% incidence of lymph node metastases in the 
follicular variant slightly lesser than that of the classical papillary carcinoma 
cases and also the mean age of presentation was 33 years in comparison to 
the classical papillary carcinoma cases who had 37 years of age as the 
incidence. And also FVPTC showed less incidence of extra thyroidal invasion 
than the classical papillary carcinoma and also less calcifications in 
Sonography.  
  The frequency of prevalence of columnar cell variant, another ominous 
subtype of papillary carcinoma in the present study was 6.25%, the mean age 
being 46 years of age. They have less female incidence in relation to the 
other histological variants of the papillary thyroid carcinoma. The clinical 
presentation of these was evidently an indicator of their aggressive clinical 
behavior.  In our study we found high incidence of lymph node metastases in 
comparable to the classical papillary carcinoma. The morphologic 
heterogeneity is found commonly in columnar cell variant carcinomas than 
other variants.  
The tall cell variant of papillary thyroid carcinoma is not a common 
pathologic entity with the prevalence ranged from 4% to 17% of cases.  The 
pathologists have proposed diagnostic criteria which include a composition of 
more than fifty percent tall cells, with a tall cell height of at least twice the 
width, cytoplasm eosinophilic and the nuclear features characteristic of 
papillary thyroid carcinoma. This variant is known for its rarity. In our study 
we found the prevalence of 4.17% in total number of the patients of papillary 
thyroid carcinoma (2 cases) and both of them had lymph node metastases 
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and they occurred in the fifth and sixth decade of life. Also they had equal 
gender incidence. There were no distant metastases found in our study in 
respect to the tall cell variant. Tall cell variant is high risk histological behavior 
which needs clinical suspicion and evaluation for the invasion and the 
metastases.  
The other types of histological variants include the oncocytic variant, 
encapsulated variant, clear cell and oxyphilic variant, papillary carcinoma with 
lipomatous stroma, Warthin‟s-like tumor or with nodular fasciitis-like stroma 
and cribriform papillary carcinoma have been reported in the literature and 
each variants vary in the prevalence, gender difference and also the clinico 
pathological features and they also need to be considered in the cytological 
examination. 
Thyroid calcifications within a mass are an important sonographic finding, 
and a malignant nodule may show both coarse calcifications and micro 
calcifications. Calcifications within a solitary mass can be considered an indicator 
of malignancy.  Even though the coarse dystrophic calcifications within the 
thyroid tissue are considered to be of no diagnostic value, some articles have 
suggested that they would seem to have an association with carcinoma. 
Pathologically, thyroid calcifications are divided into psammoma bodies and 
dystrophic calcifications. Psammoma bodies are described as laminated, 
basophilic, spherical concretions and are a characteristic finding of papillary 
carcinoma. Most micro calcifications on Sonography represent psammoma 
bodies, suggesting cancerous changes. 
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In our study, as per the NCCN guidelines for the suspicious sonographic 
features, it was found out that the hypoechogenic nodules were found in 39 
cases out of 48 cases of papillary carcinoma, while 8 cases out of 11 cases of 
Follicular carcinoma exhibit the same finding which explains the importance of 
sonographic examination in the diagnosis of thyroid carcinoma and the most 
malignant nodules present as Hypoechogenic structures and henceforth the 
value of suspicious sonographic features are established. 
We found micro calcifications in 33 cases of papillary carcinoma but 
surprisingly only in 2 cases of follicular carcinoma which establishes the high 
incidence of micro calcifications in the papillary carcinoma. Sonographic 
examination is also useful in establishing the extent of the tumour and the 
nodes in the neck. Also Sonography is useful for image guided FNAC to increase 
the sensitivity of the cytological diagnosis. Although computed tomography 
examination is more sensitive in establishing the extent of the tumour but it is 
avoided usually in the fear of delayed radioactive iodine studies after surgery, 
and hence CT is done only for large bulky and tumours extending substernally. 
In our study more than 70% of cases belong to the AJCC-TNM 
Stage I disease in cases of papillary carcinoma and 44% of cases 
follicular carcinoma cases belong to the same. This implies the large 
number of cases in the study with good prognosis. In a study conducted 
by Simon et al.107 in 2000 the differentiated thyroid carcinomas were 
staged and their percentages were calculated. Various studies have described 
the incidence based on AJCC 5th and 6th edition of TNM staging of thyroid 
carcinoma and hence the results may not be able to be compared to the other 
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studies. The study which based on the AJCC TNM staging 7th edition is 
compared and our study showed high percentage of Stage IV disease. Simon et 
al showed higher incidence of Stage I disease. 
In a Meta analysis, it was found that nodal metastasis was found in 36% 
of the papillary carcinoma cases and 17% of the patients with follicular 
carcinoma and 80% in children. Even though the lymph node metastases play 
an important role as prognosis in follicular carcinoma, the importance in 
papillary carcinoma is less. In our study, we found high incidence of lymph node 
metastases in papillary carcinoma (45.83% of cases) and 36.36% of follicular 
cell carcinoma cases. In all the cases of thyroid carcinoma, it was found to be 
43.33% of cases with lymph node metastasis which is higher than many of the 
cases which showed a lymph node metastasis of 28-37% of cases in various 
studies. This can be presumed due to the long duration of the thyroid swelling 
presented in many of the cases and the sensitivity of the ultrasound of the 
lateral and central neck in detecting the suspicious nodes in the thyroid 
carcinoma. 
In our study group, we found out that lymph nodes were clinically 
palpable in 10 of which three cases did not have any clinically evident thyroid 
swelling or nodules. Ultrasonographic evaluation showed suspicious nodes in 26 
cases of which 22 cases where papillary carcinoma of thyroid and 4 cases were 
follicular cell carcinoma. The lymph node metastasis is related to the histological 
variants of both papillary and follicular carcinoma. Lymph node metastases was 
found high in tall cell, columnar cell variant and less in follicular variant of the 
papillary carcinoma of thyroid.  
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The thyroid carcinoma has low incidence of distant metastases compared 
to many of the other malignancies found in the body. In our study, we found 
distant metastasis found in five cases of which three cases had papillary 
carcinoma. Although the papillary carcinoma has high propensity for lymph node 
metastases, the incidence of haemetaogenous spread is less in compared to the 
follicular carcinoma, and in our study it was found to be 18.2% of cases. 
Papillary carcinoma of thyroid has high propensity for pulmonary metastases 
which is usually detected by radiographic examination, CT while the high 
sensitivity tool being the PET-CT. The follicular carcinoma of thyroid has avidity 
toward the bony metastasis due to the genetic alterations and the nature of the 
tumour. 
In our study we found a clear relation between the primary tumor 
diameter and the development of more advanced disease. When tumor 
diameter is taken into consideration, Follicular carcinoma of the thyroid showed 
a more indolent clinical course than the papillary carcinoma of thyroid as the 
duration of the swelling taken into the consideration in contrary to some of the 
other studies which showed more indolent course in cases of papillary 
carcinoma of thyroid. 
 The tumor size adjusted risk of multifocal carcinoma was statistically 
significant in papillary carcinoma of thyroid („P” value - 0.02) with the 
multifocality found in 20% of cases with tumour diameter less than 4 cm and 
34% of cases of lesions above 4cm in diameter and there was cumulative risk of 
multifocality with increased size and the need for aggressive therapy in papillary 
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carcinoma. And multifocality was found only in tumours above 4cm in cases of 
follicular carcinoma of thyroid but the statistical correlation was not found due 
to the less number of cases in the study.  
The identification of primary tumor size as a risk factor in itself is not 
new. Many prognostic scoring systems have embraced this parameter. The 
findings from the present study are largely in agreement with those of Machens 
et al.  However, Machens et al – regardless of histological entity – found an 
increased risk of distant metastases for tumors larger than 20 mm comparable 
to 20 mm in the present study. 
Machens et al suggest pursuing aggressive diagnostic and therapeutic 
measures to rule out malignancy in any nodule exceeding 20 mm in diameter; 
these constitute about one-third of all thyroid nodules. Pursuing this strategy in 
all nodules over 10 mm would involve a far greater part of the population, and 
would therefore incur much greater costs. The present results, however, 
indicate that from a diameter of about 1 cm onwards, thyroid nodules deserve 
appropriate specialist evaluation in order to detect carcinomas in a curable 
stage. This is also advocated in the 2006 European consensus on the 
management of thyroid nodules.  
An important criterion for classifying tumors is risk. Risk, however, is a 
wide-ranging concept and can be specified for many parameters. As patients 
with differentiated thyroid carcinoma (especially the ones with lower tumor 
stages) have a long-term survival of > 95%, 14 additional parameters for 
defining risk are useful to assist in determining the classification of tumors. The 
occurrence of distant metastases, which is generally considered to be a severe 
adverse event in the course of disease progression, can be such a criterion.  
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An interesting observation in the present study is the non-trivial 
percentage of FTC patients who develop lymph node metastases particularly 
above the diameter of tumour of 4 cm compared to papillary carcinoma of 
thyroid where lymph node metastases occur in all diameters of the tumour but 
increased risk found statistically above 4cm. (Table 15/Fig 15). This is 
somewhat contradictory to the supposedly primarily hematogenic spread of 
FTC. However, these lymph node metastases are almost exclusively caused by 
carcinomas with extra-thyroidal growth. It is conceivable that tumor cells that 
spread outside the thyroid can also be transported via the lymphatic pathways.  
FTC patients with extra-thyroidal tumor growth should probably undergo 
a central compartment neck dissection in order to ascertain their lymph node 
status. As can be seen from the curves of tumor size adjusted cumulative risks, 
some tumors start metastasizing at considerably smaller diameters than others. 
Should one want to make a more accurate analysis of the risk of metastases 
(whether in addition to, or as a replacement of existing morphologic 
classification) genetic analysis is unavoidable. 
The surgery for papillary carcinoma range from hemithyroidectomy to 
total thyroidectomy and also neck node dissection based on the clinical and 
radiological findings. Indications for total thyroidectomy in our study include age 
younger than 15 years or older than 45 years, radiation history, known distant 
metastases, bilateral nodularity, extra thyroidal extension, tumour greater than 
4 cm in diameter, or aggressive variants which include the tall cell variant, 
columnar cell, or poorly differentiated and also for the patients who preferred 
total thyroidectomy and patients who tend to lose follow up protocol for 
  88 
recurrence and metastasize. The controversy between the conservative surgery 
to aggressive surgery has less role in experienced surgeons hands and total 
thyroidectomy should be preferred for all cases of thyroid carcinoma particularly 
due to the risk of multifocality of well differentiated tumours. 
 The role of prophylactic central compartment node dissection in 
medullary carcinoma of thyroid is well known. Studies have shown the 
importance of prophylactic central compartment neck node dissection in high 
risk patients who have high chances of micrometastasis to the central 
compartmental neck nodes.  In our study, when lymph nodes are not enlarged, 
the prophylactic central compartmental dissection was done in seven cases 
based on the size of the tumour, high risk variants, and involvement of 
surrounding structures.  
The limitations of the study are that it is a retrospective study of the 
thyroid carcinoma where as other disorders of thyroid was not studied for the 
comparisons. Also the sensitivity of the FNA and other modalities in establishing 
the diagnosis of the thyroid carcinoma preoperatively could not be observed. 
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CONCLUSION 
 
  We found the incidence of thyroid cancer was higher in female 
gender with ratio of 5:1 and the incidence of thyroid cancers 
predominantly occur in the fourth decade of life. The most common mode 
of clinical presentation was thyroid swelling which was higher than those in 
comparative studies and the Ultrasonographic features play an vital role in 
finding the nodules suspicious for malignancy. Fine needle aspiration cytology 
is an inexpensive accurate and practical investigation for evaluation of 
thyroid carcinomas and the molecular studies may play an important role in 
establishing the diagnosis and evaluation in future era. The histological variants 
of papillary and follicular cell carcinoma have different clinical behavior and 
they need to be evaluated for the different incidence of metastases to node 
and distant areas. The size of the tumour is an individual parameter that helps 
to find out the risk for multifocality, invasion and the nodal metastases in both 
the papillary and follicular carcinoma of thyroid. The extent of surgery needs to 
be on the extent of the lesion, nodal metastases and the risk category. 
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SUMMARY 
In summary, a total number of 60 patients with thyroid cancer were 
evaluated in the study period from June 2010 to May 2012 at Madurai 
Medical College retrospectively. The occurrence of thyroid cancer was 
maximum in the 4th decade of life followed by the 5th decade of the life. Female 
gender outnumbered males with a ratio of 5: 1 in this study, the commonest 
symptom of thyroid malignancy was a painless swelling in the front of the 
neck (95% of the patients) and the duration of symptoms varied greatly; with 
70% of the patients presenting with a duration of less than 1 year. FNAC was 
helpful in establishing the diagnosis in 80% of cases. Ultrasonography of the 
neck was found to be very sensitive tool in thyroid carcinoma to find out the 
features suspicious of the malignancy and the impalpable nodal metastases. 
 
The most common histopathological type was papillary carcinoma 
thyroid (80%); followed by follicular carcinoma thyroid (18.33%) and one case 
of the anaplastic carcinoma. The age of presentation, gender incidence and the 
clinical presentations varied between the histological variants of papillary and 
follicular carcinoma of thyroid. The diameter of the tumour was found to be an 
independent parameter and statistically correlates with the morphological 
parameters of the thyroid carcinoma that include the multifocality, extra 
thyroidal invasion, lymph node and distant metastases and were statistically 
correlated. Large number of the patients in this study belonged to the high risk 
category as per AMES Categorization criteria and also to the Stage I disease by 
AJCC (2010) TNM classification system. Total thyroidectomy was the common 
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procedure required for the treatment for the thyroid malignancies and the 
extent of the lymph node dissection depends on the level of lymph node 
involvement and the prophylactic lymph node dissection in well differentiated 
thyroid cancers are needed in high risk patients. The common complications 
commonly found in the study were vocal cord palsy and the transient 
hypoparathyroidism. 
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ANNEXURE - II 
PROFORMA 
 
 
Unit :  I.P. No. :  Sl. No. :  
Name :  Age :  Sex :  
DOA :  DOO :  DOD :  
 
 
I.  Chief Complaints :  
 
 
 
 
 
 
 
II.  History of Present Illness   
 1. Swelling in the Neck :  
  a.  Onset  :  
  b. Duration :  
  c. Rate of growth  :  
  d. Associated with pain  :  
 2. Pain   
  a. Duration :  
  b. Character  :  
  c. Radiation  :  
 3. Pressure effect   
  a. Dyspnoea  :  
  b. Dysphagia  :  
  c. Hoarseness of voice :  
 4. Symptoms of Thyrotoxicosis :  
 5. Symptoms of Hypothyroidism :  
III.  Past History :  
  xv 
IV.  Local Examination   
 1. Swelling in anterior aspect of Neck :  
  a.  Size  :  
  b.  Surface  :  
  c.  Movement with deglutition  :  
  d.  Edge  :  
  e.  Lower Borders  :  
  f.  Other Swellings  :  
  g.  Dilatation of veins  :  
  h.  
Congestion of face on 
raising the hand  
:  
  i.  Consistency  :  
  j.  Plane  :  
  k.  Mobility  :  
  l.  Cervical Lymph nodes  :  
V.  Ultrasonographic findings   
 1.  Solid/ Hypoechogenic structure :  
 2.  
Heterogeneous echogenic 
structure 
:  
 3.  Irregular margins :  
 4.  Extra-glandular extension :  
 5.  
Fine punctuate internal 
calcifications. 
:  
 6.  Tracheal infiltration :  
 7.  Nodes if found  :  
  a. Suspicious :  
  b. Insignificant :  
VI.  Vocal cord status :  
VII.  Thyroid function tests :  
  xvi 
VIII.  Metastatic work up :  
IX.  FNAC Report   
 1.  
Papillary Lesions of suspicious of 
papillary carcinoma. 
:  
 2.  Follicular/Hurthle cell neoplasms  :  
 3.  
Follicular cells of undetermined 
significance 
:  
 4.  Medullary carcinoma :  
 5.  Insufficient biopsy, non diagnostic :  
 6.  Lymphoma :  
 7.  Anaplastic carcinoma :  
X.  Repeat FNAC finding if it was done :  
XI.  Procedure performed :  
 1. Total Thyroidectomy :  
 2. 
Hemithyroidectomy followed by 
completion thyroidectomy 
:  
 3. Near total thyroidectomy :  
 4. Hemithyroidectomy :  
XII.  Lymph node dissection   
 1. 
MRND and central compartmental 
Neck dissection 
:  
 2. 
Central Compartmental Neck 
Dissection 
:  
 3. 
Therapeutic central Compartmental 
Neck dissection 
:  
XIII.  Intra operative findings :  
XIV.  Post operative biopsy report   
 1. Histological variant :  
 2. Type of histological variant :  
 3. Multifocality :  
 4. Extrathyroidal extension :  
XV. Radio Therapy :  
XVI.  Complications  :  
XVII.  Treatment of Complication  :  
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ANNEXURE – III 
 
MASTER CHART 
 
Key to Master Chart 
 
 
Sl.No. - Serial number 
Age - Age of the patient 
Gender   
 M - Male 
 F - Female 
Variants   
 F - Follicular cell carcinoma 
 P - Papillary cell carcinoma 
Thyroid profile 
 H - Hyperthyroidism 
 N - Normal 
Vocal cord Status 
 U - Unilateral Vocal Cord Palsy 
 No - No Vocal Cord Palsy 
FNAC finding   
 P - Papillary carcinoma or features of papillary carcinoma 
 FCN - Follicular/Hurthle cell Neoplasms 
 FCUS - Follicular cells of undermined significance 
 A - Anaplastic carcinoma 
 N  Non diagnostic 
Histological variant  
 CL - Classical Papillary carcinoma 
 FV - Folicular variant of Papillary carcinoma 
 C - Columnar variant  
 T - Tall cell variant 
 H - Hurthle cell variant 
 F - Follicular carcinoma 
 A - Anaplastic carcinoma 
  xviii 
 
AMES 
  
 LR - Low Risk 
 HR - High Risk 
Primary Surgery 
 TT - Total Thyroidectomy  
 NT -  Near Total Thyroidectomy 
 HT -  Hemi Thyroidectomy 
 HTCT - 
Hemi Thyroidectomy followed by completion 
Thyroidectomy  
 NA - Not Applicable 
Neck Dissection 
 No - No Neck Dissection 
 FND - Functional Neck Dissection 
 CLND - Central compartment Lymph Node Dissection 
 PCLND - Prophylactic Central compartment Lymph Node 
Dissection 
 
Complications   
 T - Transient Hypoparathyroidism 
 P -  Vocal Cord Palsy 
 NO - No complications 
 NA - NA 
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1.  17 F P N No 1-2 P No No No No CL I LR TT No No 
2.  16 F P N No 2-4 P No No No No CL I LR TT No No 
3.  23 F P N No 4-6 P No No Yes No CL I HR TT CLND No 
4.  27 F P N No 0-1 P No No No No CL I LR HT No No 
5.  26 F P N No 2-4 P Yes No Yes No CL I HR TT FND No 
6.  29 F P N No 1-2 P No No No No FV I LR TT No No 
7.  21 F P N No 6-8 P No No Yes No CL I HR TT CLND T 
8.  27 F P N No 4-6 P Yes Yes Yes No CL I HR TT FND No 
9.  25 F P N U >8 P Yes Yes Yes No CL I HR NT FND No 
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19.  34 F P N No >8 P No No No No FV I HR TT PCLND No 
20.  33 F P N No 2-4 P No No No No CL I LR TT No No 
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41.  34 M P N No 2-4 P Yes Yes Yes No T IVA HR TT FND No 
42.  34 M P N No 4-6 P Yes No Yes No CL IVB HR TT FND P 
43.  38 M P N No 1-2 P Yes Yes No No CL III HR TT CLND No 
44.  43 M P N No 4-6 P No No No No CL III HR TT PCLND No 
45.  52 M P N U >8 P Yes Yes Yes Yes FV IVC HR NT FND No 
46.  61 M P N No 4-6 N Yes No No No CL III HR TT PCLND No 
47.  72 M P N No 4-6 P No No Yes No C I HR TT CLND No 
48.  77 M P N No 1-2 P No No No No CL II LR TT No No 
49.  24 F F N No 4-6 FCN No No No No F I HR HTCT No No 
50.  27 F F N No 2-4 FCUS Yes No No No F I HR TT PCLND No 
51.  33 F F N No 1-2 N No No No No F I LR HTCT No No 
52.  38 F F N No 6 FCN No No No No F I HR TT No T 
53.  30 F F N U 4-6 FCN Yes Yes Yes Yes H II HR NT FND No 
54.  41 F F N No 2-4 FCN No No No No F I LR HTCT No No 
55.  49 F F N No >8 N No Yes Yes No H IVA HR TT FND T 
56.  46 F F N No 4-6 FCN No No Yes No F III HR TT FND No 
57.  51 F F N No 2-4 FCUS No No No No F II LR HTCT No No 
58.  37 M F N U 6-8 FCN Yes Yes Yes Yes H IVC HR NT FND T 
59.  55 M F N No 4-6 FCUS No No No No F III LR TT No No 
60.  67 F A N U 4-6 A Yes No No No A IVA HR NA NA No 
 
 
